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1.  Introduction 
The proposal of a genetic basis of cancer together with the advances in molecular 
genetics has provided a deep view into cancer pathogenesis. Nowadays this has 
made the vision become more obvious about the multistep evolution of cancer by 
somatic cellular genes mutations and clonal selection of variant progeny with 
increasing aggressive growth properties. In colon cancer, the essential genetic facts 
in the understanding of its biology and genetics have emerged and are slowly making 
their way even into the clinic to contribute in the early diagnosis, therapy and follow-
up of colon cancer.  
 
Colorectal cancer (CRC) may develop in several different contexts. The variation in 
their clinical behaviour and response to therapy exists through various genetic 
backgrounds and molecular profiles. Based on these varieties, CRC can present as I. 
pure sporadic, sporadic in the context of inflammatory bowel disease (75-80%) or in 
II. familial clusters (15-20%) mostly within hereditary familial CRC syndromes 
(Cardoso J et al, 2007; Calvert PM et al, 2002).  Several patients with sporadic CRC 
carry a familial risk genotype, but have no clear characterized hereditary disease 
(Goldgar DE et al, 1994; Easton DF, 2008).   
 
Hereditary nonplyposis colon cancer (HNPCC) and familiar adenomatous polyposis 
(FAP) are the most common and well defined genetic diseases with typical early 
onset of cancer (Cheah PY, 2009). The genetic screening of families has provided 
early detection of familial forms of CRC and hence has improved the survival of 
patients with hereditary variants compared to patients with sporadic types (Lynch HT 
& de la Chapelle A, 2003).   
 
The first multistep genetic model of colorectal carcinogenesis was proposed by 
Fearon and Vogelstein, based on the observation of specific genetic changes in 
benign and malignant lesions (Fearon &Vogelstein, 1990). The main features of this 
model are mutational activation of oncogenes and inactivating mutation of tumour 
suppressor genes. The total accumulation of genetic mutations in at least four or five 
genes is of more importance than the order in which these mutations occur. This 
model is still considered valid, although a number of genetic events need to be added 
in order to get the whole picture. 
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The figure demonstrates the main genetic events in the adenoma carcinoma sequence. Two distinct pathways; 
namely chromosomal instability (CIN) and microsatellite instability (MIN) are linked throughout colon cancer 
development. (Liang Cheng, John N. Eble: Molecular surgical pathology, 2013. © Springer Science + Business 
Media). Note: the abbreviation MSI used instead of MIN for microsatellite instable cases throughout the study. 
  
 
1.1. Molecular pathways in colorectal carcinogenesis 
A simple model of two genetic molecular pathways either microsatellite instability 
(MSI) or chromosomal instability (CIN) has been initially suggested (Lengauer C et al, 
1998). More recently, a third non genetic but rather epigenetic instability pathway was 
also recognized. Evidence of overlapping between pathways’ features has been 
observed in some tumours (Goel A et al, 2003). 
 
1.1.1. Chromosomal instability pathway  
The observation of high-degree CIN in colon cancer has initiated the argument 
around the role of CIN in cancer onset and/or progression. CIN refers to an 
accelerated rate of losing or gaining whole chromosomes or large parts of 
chromosomes during cell division resulting in karyotypic variability from cell to cell. 
The consequence is an imbalance in chromosome number (aneuploidy), 
subchromosomal genomic amplifications, and an increased rate of loss of 
heterozygosity (LOH) (Michor F et al, 2005). 
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The molecular basis for CIN and the underlying genetic alteration in most CIN 
cancers have not been yet identified. The DNA genetic alterations are not randomly 
distributed throughout the genome but target specific genes and CIN causative 
mutations are selected for tumour cells that enhance the rate of LOH at tumour 
suppressor genes and up regulate oncogenes by allelic gains (Grady WM, 2004). 
 
Chromosome loss is a common molecular defect in colon cancer similar to other solid 
tumours. Many investigators explored the relationship between CRC and allele 
losses at different chromosome loci, where one or more tumour suppressor genes 
are located (Nowak MA et al, 2002). Chromosomal instability was found in 70% of 
sporadic CRC, where some of them exhibit recurrence that represents basic 
chromosomal changes for cancer initiation and progression (Cho KR & Vogelstein B, 
1992). The prognostic value of LOH in colorectal cancer was investigated but its 
significance still remains uncertain (Weber JC et al, 2001). 
 
Advances in scientific research have improved the methodological approaches for 
CIN measurement such as DNA flow cytometry, allelic imbalance assays (tumour 
allelotyping/LOH analysis), fluorescent in situ hybridization, and recently, comparative 
genomic hybridization (CGH). Currently, CGH microarrays (array CGH) have 
contributed innovative advances in the field due to their ability to identify 
chromosomal and segmental amplifications and deletions with higher resolution 
(Geigl JB et al, 2008). 
 
1.1.2. Microsatellite instability pathway 
Microsatellite instability is considered a definitive subtype of CRC with a well defined 
histopathological and therapeutic profile. This pathway is characterized by the loss of 
mutation mismatch repair (MMR) gene function resulting in tumour-specific frame-
shift mutations in stretches of short repetitive DNA sequences (i.e. microsatellite 
repeats) distributed along the genome (Ionov Y et al, 1993; Thibodeau SN et al, 
1993). Notably, MSI tumours increase nucleotide mutation rates, which remain 
throughout DNA replication resulting in alleles of different size but share near-diploid 
chromosomal contents (Parsons R et al, 1993; Bhattacharyya NP et al, 1994; 
Eshleman JR et al, 1998; Jacob S et al, 2002). 
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Germline defects in MMR genes occur in 5% of all CRC patients with a positive 
family history, which is the hallmark of the well-known hereditary non-polyposis 
colorectal cancer syndrome (Lynch HT & Lynch J, 2000). The MSI phenotype found 
in about 15% of all sporadic colorectal cancer is usually not associated with gross 
chromosomal changes (Hoang JM et al, 1997; Peltomaki P, 2001). 
 
The most frequently mutated genes in the MSI pathway are transforming growth 
factor beta receptor II (TGFBR2), Myc-associated factor X (MAX) and Insulin-like 
growth factor 2 receptor (IGF2R). Inactivating mutations of TGFBR2 is found in 
approximately 90% of all CRC with MSI phenotype where mostly both alleles are 
affected (Parsons R, 1995), Hence it is suggested to play an important role in the 
development of MMR deficient colorectal tumour (Grady WM et al, 1998).  
 
In sporadic CRC, promoter hypermethylation of MutL homolog 1 gene (MLH1) is the 
key (Issa JP, 2008). The MMR state can be assayed immunohistochemically and/or 
by PCR microsatellite analysis with the Bethesda panel of microsatellite markers 
used routinely in clinical practise with a high prognostic and predictive value (Vilar E 
& Gruber SB, 2010; Geiersbach KB & Samowitz WS, 2011).  
 
Currently due to the frequent association of a specific histological lesion known as 
sessile serrated adenomas or polyps (SSA/P) with increased risk for CRC 
development; a new distinct independently alternative pathway known as serrated 
pathway was proposed. This is molecularly characterized by BRAF mutation and 
promoter methylation of different genes, especially MLH1 gene (Jass JR et al, 2000; 
Huang CS, 2004). 
 
1.1.3. Epigenetic instability pathway 
Pathological epigenetic changes, non-sequence based alterations inherited through 
cell division, are considered to be involved in the regulation of transcription. An 
intense DNA hypermethylation has been observed in the gene promoter associated 
CpG sites. The CpG island methylator phenotype (CIMP) was described as a distinct 
pathway by epigenetic silencing and inactivating mutations (Egger G et al, 2004). 
 
Epigenetic changes include global DNA hypomethylation, hypermethylation, gene-
specific hypo- and hyper-methylation, chromatin alterations, and loss of imprinting. 
As a net result, these changes may lead to abnormal activation of growth promoting 
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genes or abnormal silencing of tumour suppressor genes (Feinberg AP & Tycko B, 
2004). Gene specific hypermethylation of normally unmethylated promoters applies 
to many tumour suppressor genes including Wnt signalling genes, like APC in 
colorectal cancer (Feinberg AP et al, 2006). 
 
Germline epigenetic changes were recently reported. HNPCC cases for which 
germline mutations in none of the MMR genes could be demonstrated the 
hypermethylation of the MLH1 gene or MutS homolog 2 (MSH2) gene was found 
functionally equivalent to inactivating mutation that producing a clinical phenotype 
similar to HNPCC (Chan TL et al, 2006; Hitchins M et al, 2005; Suter CM et al, 2004).  
 
Loss of imprinting (LOI) of IGF2 is a common epigenetic variant in adults which is 
associated with increased risk for CRC (Cui H et al, 2003). By testing gene promoter 
methylation, quantitative DNA analyses of methylations provide more useful 
information than methylation-specific PCR for the determination of CIMP (Ogino S et 
al, 2006). 
 
1.2. Tumour suppressor pathway 
Tumour suppressor genes (TSGs) are considered the safeguards of the cell. The 
importance of TSGs is related to the protective function of the protein products 
against the cell step on the path to cancer. These proteins are implicated in several 
cellular processes like cell cycle arrest and programmed cell death, indicating its 
fundamental roles in maintenance of cellular homeostasis.  
 
It is well recognized that germline mutations of TSGs manifest as heritable cancer 
predisposition syndromes (Malkin D et al, 1992). Generally, one copy of a TSG 
suffices to control cell proliferation. The demand for two genetic events (Two “hits”) 
that inactivate both gene alleles was defined and proposed for giving a selective 
growth advantage to the cell (Knudson AG, 1993; Vogelstein B & Kinzler KW, 2004). 
TSGs may be partially altered or completely depleted by many genetic events such 
as missense mutation at gene residues essential for its activity; or by nonsense 
mutations that result in a truncated protein as well as through deletions or insertion of 
various chromosomal sizes (Vogelstein B & Kinzler KW, 2004). 
 
However, an epigenetic mechanism such as DNA methylation has also been 
recorded for TSGs inactivation (Esteller M, 2002). Recently and away from the two hit 
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theory, a new class of TSGs with haploid insufficiency have been hypothesized. This 
includes only one genetic event affecting one allele required to cause functional 
inactivation whereas the single remaining functional allele is insufficient to bring 
about a wild- type condition and giving the cell selective growth advantage, when 
challenged by carcinogens (Macleod K, 2000). 
 
Tumour protein 53 (TP53) gene is an ideal model for TSGs, it has been widely 
recognized and was entitled as the ‘Molecule of the Year’ (Lane DP, 1992). Studies 
have implicated the p53 protein as important transcription factor and a multifunctional 
protein. In its normal condition it represents an important factor in tumour 
surveillance. Based on these facts p53 was denoted guardian of genome (Vousden 
KH & Prives C, 2005). Protein 53 is involved in multiple pathways, namely 
differentiation, senescence, antiangiogenesis, cell cycle arrest and programmed cell 
death (Lane DP, 1992; Vousden KH & Lu X, 2002; Levine AJ et al, 2006).  
 
Normally, p53 expression is induced by cellular stress such as genetic damage, 
radiation or imbalance of mitogenic signals which in turn promotes p53 mediated cell 
growth inhibition via transcriptional activation of cyclin inhibitors like p21. It then 
ultimately promotes cell death through apoptosis via transcriptional activation of 
genes such as Bcl-2 associated X (BAX) when the DNA repair machinery cannot 
cope with the DNA damage load. In absence of cellular stress, the p53 interacts with 
its main regulator Mouse douple minute homolog 2 (Mdm2) and other proteins 
keeping p53 expression at a lower level to avoid otherwise harmful effects on normal 
growth and development (Kubbutat MH et al, 1997). 
 
TP53 is considered a typical TSG, fulfilling the cardinal criteria of the ‘two-hit’ 
hypothesis. This was verified by Baker et al. who reported a mutation in one copy of 
the allele in combination with deletion of the other allele in human colon cancer 
(Baker SJ et al, 1989). TP53 is found mutated in more than 50% of human cancers. 
Since TP53 is a tumour suppressor gene, protein function is repressed or lost by 
mutations, most frequently missense, or deletion of the entire or part of the gene. 
This mostly occurs in certain gene regions encoding the DNA binding domain. Such 
mutations impair protein and target DNA binding by disrupting the structure of the 
domain (Harris CC, 1993). 
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Since TP53 proved to be halpoinsufficient in studies of mice with a heterozygous p53 
status it turned out not to be an ordinary TSG (Venkatachalam S et al, 1998). Only 
one genetic event can be sufficient to silence the protein. Thus, TP53 does not follow 
in all aspects the usual mechanism of TSGs. Furthermore, a mutated p53 protein 
may inhibit normal activity by interfering with wild-type p53 proteins during the 
formation of homotetramers, the functional p53 unit. The tetramer is thereby 
deactivated in a dominant-negative fashion, despite only one single p53 mutant 
protein participating in oligomerization (McLure KG & Lee PW, 1998). 
 
1.3. The genomic landscape of colorectal cancer  
The earliest and rate limiting genetic event in colorectal tumour initiation very often is 
a mutation of the adenomatous polyposis coli (APC) tumour suppressor gene on 
chromosome 5q21. This is frequently observed at the aberrant crypt foci (ACF) stage 
in relation to the degree of dysplastic changes that occurs in over than 80% of colon 
adenocarcinoma (Powell SM et al, 1992; Leslie A et al, 2002). APC acts as a tumour 
suppressor gene by regulation of the intracellular level of ß-catenin, a key member of 
the Wnt signal transduction pathway (Korinek V et al, 1997; Morin PJ et al, 1997; 
Smits R et al, 1999). The second mutational hits is distributed according to the 
resulting level of residual ß-catenin down-regulating activity (Powell SM et al, 1992; 
Miyoshi Y  et al, 1992; Lamlum H et al, 1999; Albuquerque C et al, 2002).  APC gene 
germline mutation is either inherited or spontaneously as occurs in FAP or one of its 
variants. This in turn leads to an increase in the rate of initiation of colon adenomas 
and inevitable progression to carcinoma unless the intestine is not resected surgically 
(Grady WM & Markowitz SD, 2003; Kinzler K.W. & Vogelstein B, 1996). 
 
Mutation activation of the rat sarcoma (RAS) oncogene is a major part in the 
molecular genetic analysis of colorectal cancer. It is found in at least 50% of 
colorectal adenomas larger than 1 cm in size and in carcinomas, but is infrequent in 
adenomas smaller than 1 cm in size (Forrester K et al, 1987; Vogelstein B et al, 
1988). Alternatively, mutations in other oncogenes like BRAF that encodes other 
members of the RAS pathway are often found among adenomas (Beach R et al, 
2005). Activation of this signalling pathway results in an increase of the 
transcriptional activation of target genes involved in cell proliferation and apoptosis 
(Kim EC & Lance P, 1997). 
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Loss of all or part of the long arm of chromosome 18 (18q) was found in at least 50% 
of large adenomas and 75% of carcinomas (Vogelstein B, Fearon ER, 1988; 
Vogelstein B, Fearon ER et al 1989; Jen J, 1994). The Deleted in colorectal 
carcinoma (DCC) tumour suppressor gene was suggested first; later SMAD2 and 
SMAD4 tumour suppressor genes were indentified in this region. These genes are 
involved in the Transforming Growth Factor ß (TGF-ß) signalling pathway, an 
important pathway in the control of cell proliferation, differentiation, migration and 
apoptosis. TGFBR2 mutations are also frequently found to affect TGF-ß signalling in 
CRC, mainly among MSI tumours but also in microsatellite stable tumours (Keino-
Masu K et al, 1996; Cho KR et al, 1994; Heldin CH et al, 1997; Duff EK & Clarke AR, 
1998; Grady WM et al, 1999). 
 
Loss of the short arm of chromosome 17 (17p) is characteristic for colon cancers. 
TP53 tumour suppressor gene is mapped to this chromosomal region and is 
considered to be a major colon cancer candidate gene. Inactivation of both TP53 
gene alleles can be detected in most intestinal tumours. Mutations in this gene are 
found in association with the transition from late adenoma to carcinoma and then 
supposed to be a late event as observed in advanced colon malignancies rather than 
in the early stages (Lane DP, 1992; Harris CC, 1993; Vogelstein B et al, 1988; Baker 
SJ, 1990).  
 
Scientists have detected more than 70% LOH at chromosome 17p and point 
mutation of the remaining allele in greater than 50% of sporadic CRC (Baker SJ et al, 
1989; Harris CC, 1993), TP53 genetic alterations can be measured as aberrant 
overexpression in immunohistochemical assay, either by direct DNA sequencing or 
by 17p LOH analysis (Slebos RJC et al, 1996; Baast IO et al, 1994). A p53 
expression was used as a marker for TP53 gene mutation, since up to 75% showed 
agreement with missense mutation (Erhan Y et al, 2002; Guttmejer A N et al, 2000).  
 
Currently new genes have been proposed to be implicated in colon cancer 
development and metastasis. Examples include gain of chromosome 20q observed 
in adenoma and Aurora Kinase (AURKA) that represents a candidate oncogenes 
located at 20q13.2 (Carvalho B et al, 2009). Cycline-dependent kinase 8 (CDK8) 
located within the frequently amplified chromosome 13 (13q12) was suggested to 
display oncogenic characteristics (Firestein R et al, 2008). Moreover, SMAD7 is 
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maps to the 18q locus and has gained a lot of attention (Broderick P et al, 2007). 
Some of the late chromosomal aberrations suggested are loss of the 8q arm, but not 
so far tumour suppressor gene has been identified here. Protein tyrosine 
phosphatase type IVA 3 (PTP4A3 or PRL-3) is the other gene mapping to the region 
8q24.3 amplified in late CRC stage and related to metastasis (Saha S et al, 2001).   
 
1.4. PTEN tumour suppressor gene  
 
The novel candidate gene PTEN (phosphatase and tensin homolog deleted in 
chromosome ten), is also known as mutated in multiple advanced cancer (MMAC) or 
as transforming growth factor-ß regulated and epithelial-cell-enriched phosphatase 
(TEP1). It has been identified as a tumour suppressor gene for its lipid phosphatase 
activity in dephosphorylating the 3-phosphoinositide products (PIP3) of the 
phosphoinositid-3-kinase (PI3K), thereby resulting in a concomitant decrease in AKT 
activity, which initiates signals for cellular growth, proliferation and survival 
(Maehama T & Dixon JE, 1999; Lee JO et al, 1999; Georgescu MM et al, 1999). 
 
 
 
    Active site amino acids (123-130) 
 
 
 
Schematic figure for PTEN protein  
 
 
        Phosphatase domain (amino acids 14-185)      
 
        C2 (libid membrane-binding) domain (amino acids 190-350) 
 
        Carboxy- terminal region (amino acids 351-400) 
         
         PDZ-binding domain (amino acids 401-403) 
 
 
The PTEN gene spans 105 kb that map to chromosome sub-band 10q23.3 and is 
divided into nine exons (Steck PA et al, 1997; Li J et al, 1997). The PTEN protein 
contains two key domains: the phosphatase domain and the lipid membrane binding 
domain. Both are required for its tumour suppressor functions. In addition to the 
important role of the lipid phosphatase activity for tumour suppression, other 
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functions connected to these domains were recently described. Specially, PTEN was 
detected in the nucleus of both normal and neoplastic cells, which gave PTEN gene 
more roles in cellular regulatory mechanisms (Chow LM & Baker SJ, 2006). 
 
Independently of its lipid phosphatase activity, PTEN has a tumour suppressor 
function in the anaphase-promoting complex (ANAPC) and its regulator E-cadherin 
(CDH1) in the nucleus. Altered ANAPC–CDH1 activity has been implicated in 
multiple tumour types (Song MS et al, 2011). Furthermore, PTEN was found to 
participate in regulation of TP53 protein level and activity, through both phosphatase 
dependent and independent mechanisms (Li AG, 2006). 
 
The frequent loss of PTEN function, through deletion, mutations, and/or decreased 
expression, is observed in hereditary cancers as well as in many sporadic primary 
cancers. Germline and somatic mutations found mainly in the protein coding region 
involve both the phosphatase domain and the poly (A)6 tracts (Dahia PL, 2000; 
Bonneau D & Longy M, 2000). Most of the germline and somatic mutations were 
nonsense, frameshift and splice mutations resulting in truncated protein (Ali IU et al, 
1999; Bonneau D & Longy M, 2000).  
 
Germline mutations of PTEN are found in hereditary autosomal dominant cancer 
syndromes, collectively known as PTEN hamartoma tumour syndromes (PHTS). 
PHTS is characterized by multiple hamartomas in many tissues including the 
gastrointestinal tract. An increased risk of cancer in the breast, thyroid, and 
endometrium is characteristic of many of these syndromes (Waite KA & Eng C, 
2002).  
 
Hemizygous allelic deletion was almost always responsible for PTEN inactivation in 
various sporadic tumours, with a frequency approximating 60-80% (Ali IU et al, 1999; 
Hollander MC et al, 2011). At the same time, PTEN inactivation by somatic mutations 
is found with different frequency rates through different mechanisms. Additionally 
more than one mechanism was found in a single tumour type, in which bi-allelic 
PTEN inactivation was not the predominant mechanism (Hollander MC et al, 2011; 
Ali IU et al, 1999). 
 
In many sporadic cancers, PTEN is mutated in one allele. But in other tumours PTEN 
was found to be progressively lost without any evidence of even monoallelic mutation 
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(Monte NM et al, 2010). Thus, the mechanism of PTEN inactivation with loss of its 
expression in many sporadic cancers was explained with different combinations of 
genetic and epigenetic alterations while in others it was attributed to monoallelic 
deletion (Kurose K et al, 2001; Perren A et al, 1999; Zhou XP et al, 2002; Taniyama 
K et al, 2001).  
 
Epigenetic mechanisms can explain many cases in which PTEN expression is down-
regulated or even totally ablated in the absence of detectable mutation in many 
cancer types (Zhou XP et al, 2002; Nassif NT et al, 2004; Whang YE et al, 1998; 
Cairns P et al, 1997). This, for example, was observed in malignant melanomas 
(Zhou XP et al, 2000). 
 
Moreover, the loss or decrease of either PTEN protein level or function in human 
cancers has been attributed to a number of other proposed mechanisms such as 
post-translation modification of PTEN, direct and indirect PTEN inactivation by 
microRNAs, and to inappropriate subcellular compartmentalization (Salmena L, et al, 
2008; Fata JE et al, 2012; Perren A et al, 2000; Hollander MC et al, 2011).  Recently, 
studies suggested that PTEN has a dosage effect and haploinsufficiency may further 
contribute to tumorigenesis with specific tissue dependent sensitivity to the reduced 
level (Dahia PL, 2000; Carracedo A et al, 2011).  
 
1.4.1. PTEN as colorectal cancer candidate gene 
 
Regarding colon cancer, PTEN is considered a mutated candidate gene in colon 
cancer although in low frequency according to mutation frequencies recorded by 
Wood LD et al (2007). As observed commonly in other sporadic tumours, PTEN 
somatic alterations, are often associated with other genetic alterations, making a 
functional role uncertain (Wood LD et al, 2007; Hollander MC et al, 2011). 
 
PTEN inactivation was mentioned in various selected and unselected CRC studies 
with a heavy predominance for the microsatellite instable type (Shin KH et al, 2001; 
Negoro K et al, 2000).  Allelic deletions at 10q23.3 gene locus have been observed in 
approximately 30-35% of sporadic CRC (Frayling IM et al, 1997). On the other hand, 
PTEN somatic mutations were detected in approximately 19% of microsatellite 
instable (MSI+) CRCs in the coding region, almost exclusively in one of the two poly 
(A)6 tracts in exon 7 and 8 (Guanti G et al, 2000; Zhou XP et al, 2002). By contrast, 
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only 5-10% of PTEN somatic mutations have been detected in MSI unknown or 
microsatellite stable (MSI-) sporadic colorectal tumours (Shin KH et al, 2001; Guanti 
G et al, 2000).   
 
Gene silencing by promoter hypermythylation was considered as a major mechanism 
through which the PTEN gene may be inactivated in colon cancer. This is more 
important than the other mechanisms, particularly in MSI+ colon tumours, where 
hypermethylation was taken in account as the “second hit” in bi-allelic PTEN 
inactivation (Goel A et al, 2004). In addition to the mixed genetic/epigenetic 
alterations reported in colon cancer; PTEN inactivation by dual mutations affecting 
both alleles was within the registered structural alterations (Nassif NT et al, 2004; 
Danielsen SA et al, 2008; Dicuonzo G et al, 2001). 
 
PTEN has been studied by immunohistochemistry in various human tissue and was 
found to be expressed in the majority (Taniyama K et al, 2001). A granular and 
punctuate manner of PTEN expression is reported in the colon throughout the 
mucosal and epithelial layers with exclusively cytoplasm predominance in normal and 
tumour cells (Taniyama K et al, 2001).  
 
Compared to normal mucosa, loss or at least reduction of PTEN expression was 
recorded for colorectal carcinoma (Hsu CP et al, 2011; Li XH et al, 2009). It has also 
been designated biologically relevant and predictively reliable whether in early 
detection of endometrial precancerious lesions or even in colon polyps and advanced 
metastatic colorectal cancer (Mutter GL et al, 2000; Waniczek D et al, 2013; Sawai H 
et al, 2008; Lin MS et al, 2011). 
 
1.5. LOH detection by microsatellite analysis  
Loss of genomic material is a defining feature of CIN in colorectal cancer whereby, 
very often, a gene is reduced to a state of homozygosity (Lasko D et al, 1991). 
Traditionally, LOH was studied by restriction length polyomorphisms (RFLP) (Lothe 
RA et al, 1988; Solomon E et al, 1987), but with the advent of PCR, polymorphic 
markers are used widely (Geigl JB et al, 2008; Gruis NA et al, 1993). If informative, 
PCR amplifying polyomorphic DNA loci with variable repeat sequences of 2-7 
nucleotides result in PCR products of different length that represent parental and 
maternal alleles of a gene, respectively (Cacev T et al, 2006). Thus, the availability of 
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a broad rang of informative markers for the human genome have made microsatellite 
assay very popular and used widely (Ellegren H, 2004; Medintz IL et al, 2000; Berti L 
et al, 2001).   
 
1.5.1. The distinction between ROH, AI and LOH  
The accurate scoring of allelic imbalances (AIs) by fluorescence based polymorphic 
microsatellite PCR method has made possible the detection of even subtle allelic loss 
in tumour cells by quantification of both size and extent of amplified products more 
precisely than to the non-quantitative methods. In contrast to MSI, where new alleles 
are generated, there is some degree of imbalances scored by calculation of the 
recorded semi-quantitative values (Skotheima RI et al, 2001).  
 
LOH, AI, and retention of heterozygosity (ROH) are different categories which reflect 
the genetic status of specific gene allele and are calculated according to the ratio of 
the peak heights of normal and tumour alleles (see section on materials and 
methods). ROH is scored when the ratio is maintained within the normal range from 
0.5 – 2, AI is scored if the ratio exceeds this range. The AI pattern can be obtained 
either by partial allelic loss or by gain/increased DNA copy number of a particular 
gene (Geigl JB et al, 2008; Skotheima RI et al, 2001). LOH is assigned in case of a 
complete loss of a wild type allele (Devilee et al 2001; Tomlinson IP et al, 2002).   
 
1.5.2. The role of tumour xenografts and LCM in the detection of LOH  
The application of the laser capture microdissection (LCM) through the successful 
separation of tumour tissue from the adjacent normal and the human tumour tissue 
implants into immunodeficient mice eliminate contamination problems and optimize 
the molecular analysis by providing pure tumour samples (Ellsworth RE et al, 2003; 
Lo KW et al, 2000; Heinmöller E et al, 2000; Harkes IC et al, 2003; Bartsch D et al, 
1999).   
 
The tumour xenografts are neoplastic human cells, supported by nonneoplastic 
murine stromal cells, which fail to amplify with primers designed from human DNA 
sequences. Tumour xenograft DNA has been shown to remain stable in relation to 
the primary tumour DNA regardless of the number of implant passage (Uronis JM et 
al, 2012; McQueen HA et al, 1991). The possibility of gaining more genetic 
instabilities during cell propagation either in cell culture or as xenografts has been 
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often suggested by researchers in many studies related to gene allelotyping. 
Evidence for such genetic instability has not yet been significantly provided (Reyes G 
et al, 1996; Hahn SA et al, 1995).  
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1.6. Aim of the study 
 
This study was undertaken to test if the patterns of molecular aberration of the PTEN 
gene are consistent with a tumour suppressor gene mechanism. To this end, tumour 
DNA from colorectal carcinoma xenografts or primary cell lines was used for gene 
sequencing and allelotyping analyses; gene expression was studied by 
immunohistochemstry. P53, a paradigm tumour suppressor gene was studied for 
comparison.  
 
Specifically, the following points were addressed: 
1. Frequencies and types of PTEN gene mutations? 
2. Frequencies of LOH compared to AI? 
3. “Two-hit” mechanism to be recorded? 
4. Patterns of gene expression, in relation to molecular aberrations 
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2. Material and methods 
 
2.1. Tumour specimens 
 
Tumour tissue and normal tissue, for comparison, were obtained from 18 patients 
who underwent colorectal cancer surgery in the Department of Surgery, University of 
Rostock, Germany. A small part of each tumour (cubes ca. 3 x 3 x 3 mm) was taken 
and snap-frozen in liquid nitrogen for storage at -80ºC by the pathologist who later 
made the dissection and final reports after overnight fixation in buffered formalin. 
Subcutaneous xenografting into immunodeficient mice and generation of primary 
tumour cell lines was performed as previously published (Linnebacher M et al, 2010). 
 
DNA was extracted from the tumour xenografts (N = 15) or the primary tumour cell 
lines (N = 2). For one case (case no. 15) as neither xenograft nor cell line were 
available tumour DNA was extracted from neoplastic glands isolated from paraffin 
sections of the primary tumour. Only tumours classified as advanced primary 
microsatellite stable sporadic standard type colorectal carcinomas (spStd CRC) were 
included in this study.  
2.2. DNA extraction 
2.2.1. DNA extraction from paraffin material 
 
Three to five 10 μm thick paraffin tissue sections were collected in a 1.5 ml micro-
tube. Sections were deparaffinized by adding 1ml xylene. After vortexting and 
centrifuging at 10,000 rpm for 5 min, xylene was removed carefully and 1 ml ethanol 
(95%) was added. Again the mixture was vortexed, followed by centrifugation at 
10,000 rpm for 5 min and careful removal of ethanol. This washing step was repeated 
once. The pellet was dried at 60°C for 10 minutes until the ethanol had completely 
evaporated. After addition of 100-200 μl digestion puffer (10mM Tris-HCl, 0.1mM 
EDTA, 0.5% Tween 20) and 10-20 μl Proteinase K (20mg ml-1) (Roche, Germany), 
tissue was incubated at 56ºC overnight, followed by inactivation of the proteinase K 
at  95ºC for 15 min. The DNA sample was obtained after cleaning the reaction 
mixture using the Wizard DNA Clean-Up System (Promega, WI, USA). 
 
2.2.2. DNA extraction from fresh tissue  
 
DNA from frozen fresh tissue and tumour xenografts was extracted using the 
Nucleo®Spin Tissue Kit (MACHERY-NAGEL, Düren, Germany). Twenty to thirty 
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cryostat sections (10μm) were placed in a 1.5 ml microcentrifuge tube containing 180 
μl cell lysis buffer and 25µl proteinase K and incubated for 24 hours at 56ºC in a 
shaking incubator until the tissue was completely digested. The following steps were 
applied according to the manufacturer’s instructions. The DNA was eluted with 80μl 
elution buffer.  
 
2.2.3. Quantitation of DNA concentration and assessment of quality 
 
The quantity of extracted DNA was determined by using the NanoDrop 
Spectrophotometer ND-1000 (Peqlab). In order to assess the DNA quality we 
amplified fragments of four housekeeping genes. PCR primers were selected from 
the human thromboxane synthase gene (TBXAS1, exon 9; GenBank accession No. 
D34621), human recombination activating gene (RAG1, exon 2; GenBank accession 
No. M29474), human promyelocytic leukemia zinc-finger gene (PLZF, exon 1; 
GenBank accession No. AF060568), and human AF4 gene (exon 3; GenBank 
accession No. Z83679), respectively, to amplify products of 100, 200, 300, and 400 
bp (Dongen JJ et al, 2003). The PCR reactions were carried out as multiplex 
reactions. PCR products were electrophoresed on 2% agarose gels containing 0.5 
mg ml-1 of ethidiumbromide. 
 
2.3. Mutation analysis 
 
Mutation analysis of the TP53 gene exons 5-8 was carried out by a mutation 
screening which is well established in our laboratory. Exon 1 of TP53 gene is a non-
coding exon. Mutations at TP53 exons 2, 3, 4, 9, 10, and 11 as well as the 9 exons of 
the PTEN gene were investigated by direct sequencing. 
 
2.3.1 Mutation screening of p53 gene by temperature gradient gel                                 
electrophoresis 
 
For mutation screening of the TP53 gene, PCR and subsequent Temperature-
Gradient Gel Electrophoresis (PCR-TGGE) were applied as published by Scholz et 
al. 1993. TGGE separates DNA fragments according to their melting properties 
allowing even separation of two double-stranded DNA fragments differing in a single 
base in a polyacrylamid gel with a linear ascending temperature gradient. To detect 
base changes in high-melting domains and to prevent melting open of this region 
which results in a loss of sequence-dependent mobility, one of the primers used in 
the PCR was provided with a GC-clamp at the 5’ end. In the presence of a mutation 
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in the TP53 gene fragment and the wild type (resulting from normal stromal tissue 
surrounding the tumour), during PCR two homodimers and two heterodimers are 
formed by denaturation and re-naturation that are separated by TGGE. After silver 
staining these four products are visible in the gel as 4 bands. In cases with no 
mutation only one band which corresponds to the homodimer of the wild type is 
visible (see figure 1). 
 
PCR for TP53 mutation screening was performed in a final volume of 50 μl 1x 
reaction buffer, containing 50 mM KCl, 1.5 mM MgCl2 (for exon 5, 6, 7), 3 mM for 
(exon 8), 200 μM of each dinucleotide triphosphate, 0,25 µM of each primer and 1.5 
U Taq DNA polymerase (Qiagen, Hilden, Germany). Sequences of primers and the 
length of amplicons are shown in appendix 1. PCR was performed by using the 
Sensoquest thermocycler (biolabproducts GmbH) with the following temperature 
profile: an initial denaturation at 95°C for 5 min, forty cycles with 30 seconds at 94°C, 
an annealing step of 30 seconds at 58°C for exons 6 and 7, and at 53°C for exons 5 
and 8, a polymerization step with 60 seconds at 72°C and a final extension at 72°C 
for 3 min. 
 
Ten μl from each PCR product mixed with loading dye (0.4% bromphenol blue, 0.4% 
xylencyanol) were electrophoresed in a 2% agrose gel containing 2% ethidium 
bromide. Water was used as a negative control, and a case with known mutation 
served as positive control. 
 
TGGE was performed on an 8% denaturing polyacrolamide gel with 1xMOPS as a 
running buffer. For easier handling the gel is covalently polymerized on a plastic film 
using the system from Diagen (Hilden, Germany). After a pre-run of 30 min at 250 V 
and 20°C to equilibrate the system, 5 μl of the PCR products mixed with 0.5 μl 
loading buffer (appendix 5) were loaded on the gel. After a run-in time variable for 
each exons, the current was switched off and the temperature gradient was adjusted 
(the T-gradient for the different exons was determined before in a perpendicular gel). 
When the system has reached the T-gradient the run was started again with a 
different running time for each exon as stated in appendix 2. To detect the DNA 
bands gels were silver-stained (appendix 5). 
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2.3.2. DNA sequencing 
 
Mutation analysis was done by Sanger DNA sequencing exons 2-4 and 9-11 of the 
TP53 gene for the negative cases by TGGE screening, and of the PTEN gene for all 
the cases. The PCR reactions were carried out with 50 ng DNA in 1x Phire Reaction 
Buffer (contains 1.5 mM MgCl2), 100 μM of each dNTPs, 0.15 μM of each primer and 
0.2 U of Phire Hot Start II DNA polymerase (Finnzymes, Finland), in a total reaction 
volume of 25 μl. Primer sequences for PCR amplification were taken from 
ncbi.nlm.nih.gov /tools/primer-blast and are shown in appendix 3. 
 
PCR reactions were performed in Sensoquest thermocycler (biolabproducts GmbH) 
using a two step protocol. After an initial denaturation step at 98°C for 30 seconds, 
38 cycles followed with 20 seconds at 98°C and 40 seconds at 72°C. A final 
extension step was done at 72°C for 3 min. Amplified products were then analyzed 
by electrophoresis in a 2% agrose gel. To remove salts, enzymes, nucleotides and 
non-incorporated primers, PCR products were treated with a combination of 
Exonuclease I and Shrimp Alkaline Phosphatase (Fermentas). Ten μl PCR product 
was mixed with 1 µl Exonuclease I and 2 µl Shrimp Alkaline Phosphatase incubated 
for 15 min at 37°C. Incubation at 80°C for 15 min was followed to inactivate the 
enzymes. 
 
Sequencing of each DNA strand in both directions (5’→3’ and 3’→5’) was done using 
the Big Dye Sequencing Kit v 1.1 (Applied Biosystems): 30-50 ng purified DNA (PCR 
product) together with 2μl Ready Reaction Mix, 2µl Sequencing Buffer and 10 pmol 
primer in a total volume of 10 μl was thermocycled as follows: initial denaturation step 
at 96°C for 5 min, 25 cycles of denaturation at 96°C for 10 seconds and annealing at 
55°C for 4 min. 
 
The cycle sequencing product was purified in order to eliminate reaction residuals i.e. 
oligonucleotides and ddNTPs using Big Dye® XTerminator Purification Kit™ (Applied 
Biosystems). As specified in the manufacturer’s protocol 10 µl of the sample were 
mixed with 45µl SAM-Solution plus 10µl XTerminator- solution for 30 min followed by 
vortexing and centrifuging for 2 min. The samples were loaded on an 8 capillary 
sequencer 3500 Genetic Analyzer (Applied Biosystems). The SeqScape software, 
version 2.7 was used in sequence analysis. 
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2.4. Assays for allelic imbalance/loss of heterozygosity 
 
To test for allelic imbalance or loss of heterozygosity, paired tumour and normal 
tissue DNA were analyzed. To interrogate the TP53 locus we used the three 
microsatellite markers D17S250, D17S1583 and 17p13.1. The PTEN locus was 
tested using the three markers D10S541, D10S579 and D10S1765. Primer 
sequences for PCR amplification were taken from ncbi.nlm.nih UNISTS. Sequences 
of primers, annealing temperatures, MgCl2 concentrations and the length of 
amplicons are shown in appendix 4. 
 
The PCR reactions were performed in a volume of 12.5 μl containing 25 ng genomic 
DNA, 200 μM of each dinucleotide triphosphate, 1x PCR Buffer, 0.5-1.0 μM of each 
primer and 0.5 units of AmpliTaq Gold DNA polymerase (Applied Biosystems). For 
amplifications we used the Sensoquest thermocycler (biolabproducts GmbH) with the 
following temperature profile: 1. initial denaturation step at 95°C for 10 min; 2. 35 
cycles at 94°C for 30 sec., annealing for 30 sec. and at 72°C for 45 sec.; 3.  final 
extension for 30 min. at 72°C. 
 
The PCR products were diluted (1:10), mixed with 0.3 μl GeneScan-500 LIZ Size 
Standard (Applied Biosystems) in 24 μl HiDi (Applied Biosystems) and denatured for 
3 min. at 95°C. The samples were run on a Genetic Analyzer 3500 (Applied 
Biosystems). Data were processed by ABI software GeneMapper version 4.0. 
 
Informative cases showed heterozygosity in the microsatellite analysis. Results were 
analyzed by comparison of the heights of the mean peaks of the tumour alleles and 
of normal alleles, calculation was performed by the following formula: AI = 
(t2/t1)/(n2/n1) where t1 and t2 are the peaks’ heights of the tumour allele 1 and tumour 
allele 2, respectively, and n1 and n2 are the peaks’ heights of the normal alleles. AI 
was scored when the ratio was < 0.5 or > 2. LOH was assigned to cases showing 
complete loss of one allele.   
 
2.5. Immunohistochemistry  
Consecutive 3-4 µm sections were obtained from the formalin fixed paraffin 
embedded primary tumours. Blocks selected to contain viable tumour without 
hemorrhage or pronounced granulocytic inflammation. Epitope retrieval was carried 
out by incubation of slides in high buffer retrieval solution (DAKO) at 97˚C for 20 min. 
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The immunohistochemical reactions were performed in an autostainer (Link,DAKO) 
according to the supplier’s protocol. Primary antibodies were mouse monoclonals 
antibodies against p53 protein (clone Do-7, DAKO) at 1:100 dilutions, and against 
PTEN protein (clone mAb6H2.1, DAKO) at 1:800 dilutions. Slides were 
counterstained with hematoxylin and mounted.  
 
P53 immunoreactions were evaluated semi-quantitatively based on the percentage of 
positive tumour nuclei. A score was applied as follows: none (0%), weak (<10%), 
moderate (10-50%), or intense (>50%). All tumours showing at least moderate (>10 
% positive tumour cells) p53 immunoreactivity were considered p53 positive. A 
histoscore (H-score) was used for evaluation of PTEN expression. Intensities of 
cytoplasmic staining of the tumour cells was graded semi-quantitatively on a 3-tiered 
scale as strong (score 2), weak (score 1) or absent (score 0), taking the 
immunostaining of vascular endothelium as an internal reference (strong). The 
proportion of cells without any immunostaining was classified as 0% (score 0), 1 - 
50% (score 1), and > 50% (score 2). The final numerical H-score for each case was 
obtained by multiplication of scores obtained in above categories.  
 
2.6. Statistical analysis 
 
All date were entered into a computerized data bank (Statistical Package for the 
Social Sciences, SPSS version 15.0). Testing for significance association between 
cross-tabulated data was done by two-sided Fisher’s exact test. P < 0.05 was taken 
as criterion for significance. 
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3. Results  
3.1. Patients’ and tumour characteristics 
 
In this study, the mean age of the patients was 71 years, (range 59 to 84 years), 13 
patients were males and 5 were females. Most of the tumours (13; 72%) were 
located in the right colon. Histologically, all the cases were colorectal 
adenocarcinomas (tubular adenocarcinomas except for one, which was a mucinous 
adenocarcinoma). Overall, 12 (67%) of the tumours were moderately differentiated 
while 6 cases (33%) were poorly differentiated. Eight patients (44%) had stage III 
tumours according to the International Union Against Cancer Classification (UICC).  
Three patients in stage IV had synchronous metastases in the liver (2 cases) or in the 
lung (1 case). Molecularly, all the cases were primary microsatellite stable sporadic 
standard type colorectal carcinomas. The clinical-pathological characteristics are in 
table 1.  
 
3.2. TP53 gene  
3.2.1. Gene mutation screening analysis  
TP53 gene mutation analysis was done both with DNA extracted from paraffin 
sections of the primary tumours as well as with DNA from the xenografts or the 
primary tumour cell lines. Mutation screening of TP53 exons 5-8 by TGGE revealed 
mutations in 13 of the 18 tumours (72%). An example of a TGGE analysis is given in 
figure 1. Most of the mutations were found in exon 8 (44%) (table 2). For the 5 cases 
in which no mutations were detected by TGGE, direct DNA sequencing of the other 
TP53 exons (exon 2-4 and 9-11) was done, but this did not reveal any further 
mutations. Results are demonstrated in table 3. 
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Table 1 
Clinical-pathological characteristics of study cases 
Character Number of cases % 
Age (Years)   
60 - 70 9 50 
70 – 80 6 33 
> 80 3 17 
Sex   
Male 13 72 
Female 5 28 
Tumour Site   
Right colon 13 72 
Left colon 5 28 
Tumour Grade   
G1 0 0 
G2 12 67 
G3 6 33 
Tumour Staging   
I 2 11 
II 5 28 
III 8 44 
IV 3 17 
Total 18 100% 
 
 
Table 2 
TP53 gene mutations distribution by exons 
P 53 
xon 
Exon 5 % Exon6 % Exon7 % Exon8 % Total % 
m/n 2/18 11 0/18 0 3/18 17 8/18 44 13/18 72 
 
m: Number of mutations detected; n: Total number of  cases 
 
 
 
 
 
        Results 
 
24 
Table 3 
TP53 gene mutations by TGGE in tumour xenografts and primary tumours  
 
XHROC: Tumour xenograft; 2T: Primary tumour; HROC: Tumour cell line; *: LCM primary tumour; M: 
Mutation; ND: Not done                       
 
Case Case Code 
TP53 gene exon number 
Exon 5 Exon 6 Exon 7 Exon 8 
1 
 
 
 
 
 
XHROC18P 0 0 0 M 
 2T15 0 0 0 M 
2 XHROC32 0 0 0 M 
 841/07 0 0 0 M 
3 XHROC39 0 0 0 0 
 2T29 0 0 0 0 
4 XHROC40 0 0 0 M 
 2T30 0 0 0 M 
5 XHROC46 0 0 0 0 
 2T34 0 0 0 0 
6 XHROC54 0 0 M 0 
 1373/08 0 0 M 0 
7 XHROC59 0 0 0 0 
 2T52 0 0 0 0 
8 XHROC60 0 0 0 M 
 2T51 0 0 0 M 
9 XHROC62 M 0 0 0 
 7373/08 M 0 0 0 
10 XHROC65P 0 0 M 0 
 2T47 0 0 M 0 
11 XHROC68 0 0 0 0 
 11142/08 0 0 0 0 
12 XHROC69 0 0 0 M 
 2T55 0 0 0 M 
13 XHROC70 0 0 0 M 
 2T57 0 0 0 M 
14 XHROC80 0 0 M 0 
 2T66 0 0 M 0 
15 XHROC82 ND ND ND ND 
 5109/09 * 0 0 0 M 
16 HROC85 0 0 0 0 
 2T64 0 0 0 0 
17 HROC86 M 0 0 0 
 2T74 M 0 0 0 
18 XHROC107 0 0 0 M 
 2T89 ND ND ND ND 
        Results 
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3.2.2. Gene locus allelotyping screening for AI and LOH 
 
Three polymorphic microsatellite markers were used to test for AI and/or LOH at 
chromosome 17p, all the markers included the TP53 gene locus. AI was scored if the 
normal/tumour ratio exceeded 0.5 or 2.0, and LOH was recorded for cases with 
complete loss of one allele (see figure 2 for representative electropherograms). The 
remaining cases were determined to have retention of heterozygosity. 
Study material for 18 cases included the primary tumours and adjacent normal 
mucosa as well as their matched xenografts, in 2 cases primary cell lines were used 
instead of xenograft. Because neither xenografts nor primary carcinoma cell lines 
were available for case no.15, DNA extracted from tumour tissue obtained by Laser-
capture microdissection was used.  
Overall, for all cases at least one of the three microsatellite markers was informative. 
Complete loss of one allele at 17p (i.e. LOH) by at least one microsatellite marker 
was observed for 13 of these cases (72%) when DNA from xenografts or cell lines 
was used. By contrast, with DNA extracted from the corresponding primary tumours 
LOH was observed in only 2 of the microsatellite analyses; for the remaining cases 
only AI was scored (10) or retention of heterozygosity (5). For case no. 15, the 
analysis resulted in AI for each of the three microsatellite markers. The results of the 
microsatellite analysis are set out in detail in table 4.  
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Table 4 
TP53 gene allelic imbalance and LOH  
Case  Case Code Chromosomal locus Overall 
D17S250 D17S1583 D17S13.1 
1 
 
 
 
 
 
XHROC18P NI NI LOH  LOH 
 2T15 NI NI AI AI 
2 XHROC32 NI NI AI AI 
 841/07 NI NI ROH ROH 
3 XHROC39 ROH ROH ROH ROH 
 2T29 ROH ROH ROH ROH 
4 XHROC40 ROH LOH  LOH  LOH 
 2T30 ROH ROH AI AI 
5 XHROC46 ROH LOH  LOH  LOH 
 2T34 ROH AI AI AI 
6 XHROC54 ROH LOH ROH LOH 
 1373/08 ROH ROH ROH ROH 
7 XHROC59 ROH NI ROH ROH 
 2T52 ROH NI ROH ROH 
8 XHROC60 ROH LOH LOH LOH 
 2T51 ROH ROH ROH ROH 
9 XHROC62 LOH  LOH  LOH  LOH 
 7373/08 AI LOH  AI LOH 
10 XHROC65P NI AI NI AI 
 2T47 NI AI NI AI 
11 XHROC68 ROH NI LOH LOH 
 11142/08 ROH NI AI AI 
12 XHROC69 NI NI LOH  LOH 
 2T55 NI NI AI AI 
13 XHROC70 AI LOH AI LOH 
 2T57 ROH AI AI AI 
14 XHROC80 AI LOH  LOH  LOH 
 2T66 ROH ROH AI AI 
15 XHROC82 ND ND ND ND 
 5109/09 * AI AI AI AI 
16 HROC85 ROH LOH  LOH  LOH 
 2T64 ROH AI LOH  LOH 
17 HROC86 LOH NI AI LOH 
 2T74 AI NI AI AI 
18 XHROC107 AI NI LOH  LOH 
 2T89 ROH NI AI AI 
 
XHROC: Tumour xenograft; 2T: Primary tumour; HROC: Tumour cell line; *: LCM primary tumour; 
LOH: loss of heterozygote; AI: Allelic imbalance; ROH: Retention of heterozygote; NI: Not informative 
(homozygote); ND: Not done                       
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3.2.3. Gene mutation and LOH synoptic analysis  
  
Combined TP53 LOH and point mutation of the gene was observed for 10 (56%) of 
the cases (chi-square p = 0.04), predicting a non-functional state of the gene. In three 
cases, TP53 mutations were found in combination with AI, and LOH without mutation 
was observed in three cases. For two tumours neither LOH nor a gene mutation were 
demonstrated. These results are summarised in table 5. 
Table 5 
 
Association of TP53 gene mutation and LOH 
TP53 LOH AI ROH Total 
Mutation positive 10 3 0 13 
Mutation negative 3 0 2 5 
Total 13 3 2 18 
 
          LOH: loss of heterozygote         AI: Allelic Imbalance        ROH: Retention of Heterozygote                     
 
3.2.4. TP53 immunohistochemistry 
 
By TP53 immunohistochemistry, staining was seen confined to the tumour cell nuclei, 
and was never found in the adjacent normal mucosa. Representative images are 
given in figure 3. Nuclear staining in at least 10% of the tumour cells was categorized 
as a positive reaction. Using this cut-off, 13 (72%) tumours were classified as TP53 
positive by immunohistochemistry 11 of which had been demonstrated to have gene 
mutation. The results are given in table 6. 
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Table 6 
Association of TP53 gene mutation state and immunohistochemistry 
 
p53 IHC 
TP53 gene mutation state  
M + M - Total 
Strong  6 1 7 
Moderate 
M+LOH- 
5 1 6 
Weak 1 0 1 
Negative 1 3 4 
Total 13 5 18 
 
        * IHC: Immunohistochemistry 
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3.3. PTEN gene 
 
3.3.1. Gene mutation sequence analysis 
 
Direct sequencing of PTEN gene exon 1-9 was carried out for the 17 xenograft 
tumours. For case no. 15, DNA obtained by laser-capture microdissection of 
neoplastic glands from paraffin-sections of the primary tumour was used, this yielded 
sufficient, amplifiable DNA (see figure 4 for images of the laser-capture 
microdissection). 
PTEN gene mutations were seen in only one of the tumours (case no. 12). However, 
this tumour harboured a total of 3 somatic point mutations in two different exons: a 
GAG>TAG mutation found in codon 7 of exon 1 as well as two additional mutations 
detected in exon 5 with a CGA>CAA at codon 130 and CGG>CAG at codon 142. 
The first mutation results in a stop codon whereas the other two mutations were point 
mutation that resulting in an amino acid changes from Arginine to Glutamine (see 
figure 5 for demonstration of sequencing analysis results). All sequencing results 
were confirmed by re-amplification and sequence analysis of an independent PCR 
product.  
3.3.2. Gene locus allelotyping for AI and LOH 
 
PTEN allelotyping was informative for all cases with at least one of the microsatellite 
markers. Complete loss of one allele (LOH) at the PTEN locus was observed in two 
tumours (11%). AI and ROH were recorded for 6 and 10 tumours, respectively. PTEN 
allelic status is set out in detail in table 7.  
3.3.3. Gene mutation and LOH synoptic analysis  
 
LOH or AI was not observed in the single case for which a PTEN gene mutation was 
found (table 8). 
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Table 7 
 PTEN allelic imbalance and loss of heterozygosity 
Case Case Code PTEN chromosomal locus  
D10S541 D10S579 D10S1765 Overall 
1 XHROC18P ROH ROH ROH ROH 
2 XHROC32 AI NI ROH AI 
3 XHROC39 ROH NI ROH ROH 
4 XHROC40 AI AI ROH AI 
5 XHROC46 ROH ROH ROH ROH 
6 XHROC54 ROH ROH ROH ROH 
7 XHROC59 LOH NI LOH  LOH 
8 XHROC60 NI ROH AI AI 
9 XHROC62 ROH NI ROH ROH 
10 XHROC65P NI AI ROH AI 
11 XHROC68 LOH  NI AI LOH 
12 XHROC69 ROH NI ROH ROH 
13 XHROC70 ROH ROH ROH ROH 
14 XHROC80 ROH NI ROH ROH 
15 5109/09 * ROH NI ROH ROH 
16 HROC85** ROH ROH ROH ROH 
17 HROC86** ROH AI ROH AI 
18 XHROC107 NI AI NI AI 
 
**: Tumour cell line; *: LCM primary tumour; LOH: Loss of heterozygote; AI: Allelic imbalance; ROH: 
Retention of heterozygote; NI: Not informative (homozygote)                                                         
 
Table 8 
  Association of PTEN gene mutation and LOH 
PTEN LOH AI ROH Total 
Mutation Positive 0 0 1 1 
Mutation negative 2 6 9 17 
Total 2 6 10 18 
 
 LOH: loss of heterozygote           AI: Allelic Imbalance      ROH: Retention of Heterozygote        
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3.3. 4. PTEN immunohistochemistry 
 
Staining of endothelial nuclei was a constant feature and is served as an internal 
control of the staining reactions. Intensities of immunostaining varied between the 
tumours. Scoring intensities, in 5 cases (28%) PTEN immunohistochemistry revealed 
strong staining of the cytoplasm and nuclei of the tumour cells, moderate staining 
was seen in 12 (67%) cases, and 1 of the cases (6%) was completely negative. 
Interestingly, this last case was the single tumour that harbored the PTEN gene 
mutations. An association between LOH/AI and intensities of immunostaining was not 
observed (see table 9 for details). 
 
Table 9 
 Association of PTEN gene allelic status and immunohistochemistry 
 
PTEN IHC 
PTEN allelic state 
LOH  AI ROH Total 
Strong 0 1 4 5 
Weak 2 5 5 12 
Negative 0 0 1* 1 
Total  2 6 10 18 
                       
                       * Case no. 12 with mutation 
                       LOH: loss of heterozygote       AI: Allelic Imbalance      ROH: Retention of Heterozygote           
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Figure 1. TP53 gene mutation screening of exon 8 by PCR-TGGE. Line 1-7, homozygote wild type; 
line 8 heterozygous mutation; line 10 and 12 homozygous mutation.  The abnormal bands (arrows) 
indicate the presence of a TP53 mutation.  C: Mutated control specimen. 
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Normal 
Tumour 
Normal Normal 
Tumour Tumour 
A. 
Figure 2. Examples of electropherograms from microsatellite analysis with D17S1583. 
Electropherograms are arranged in pairs with normal DNA in the upper lane and tumour DNA in 
the lower lane. A. Complete loss of one of the two alleles, corresponding to LOH. B. Partial loss 
of one allele, corresponding to AI. C. Homozygosity for D17S1583, this case is not informative. D. 
Both alleles present without significant differences in peak height ratios, corresponding to ROH. 
 
B. 
C. D. 
XHROC 80 XHROC 65P 
 
XHROC 59 
 
XHROC 39 
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Figure 3. Examples of TP53 immunohistochemistry. A. Intense and widespread nuclear 
immunostaining in a case of colorectal carcinoma (tumour no. 5109/09), score +++. Note absence 
of immunostaining in the adjacent normal mucosa. B. Example of score ++, strong nuclear 
immunostaining of the majority of the tumour cells. C. Example of score +, weak immunostaining of 
a minority of tumour cells. D. Example of a tumour negative by TP53 immunohistochemistry.  
A. B. 
C. D. 
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A.          B. 
Figure 4. Illustration of laser capture microdissection (LCM) of neoplastic glands from cryostat 
sections of case no. 15. A. H&E stained paraffin section as scout slide. B. Example of a section after 
LCM. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Demonstration of PTEN gene mutations by direct sequencing of the PCR product in case 
12. A. Exon 1 GAG>TAG mutation codon 7 → stop codon. B. Exon 5 CGA>CAA codon 130 and 
CGG>CAG codon 142, Arginine → Glutamine. 
 
 
A. 
B. 
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Figure 6. Examples of PTEN immunohistochemistry. A. Example of normal colonic mucosa showing 
strong (++) cytoplasmic and nuclear immunostaining of the colonic epithelium and endothelia. B. Example 
of a case with retention of strong (++) PTEN expression in tumour cells. C. Examples of weak PTEN 
expression (score +), and D. complete loss of PTEN expression. Arrows indicate endothelia that provided 
a convenient internal control of the immunoreactions.   
A. B. 
D. C. 
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4. Discussion 
Tumour suppressor genes play an important role in restraining inappropriate cell 
growth and division, as well as in regulating apoptotic cell death. This helps net cell 
number in tissue to be kept in balance and protects against cancer. Suppressor 
function of genes is mainly lost through mutational gene inactivation affecting both 
alleles. According to Knudson’s “two-hit” model, for a TSG inactivation the two gene 
alleles are functionally inactivated by a combination of genetic alterations, e. g. 
mutation of one allele and genome loss of the other allele.  
In colorectal cancer, the p53 gene is a prototype for this, as shown by synoptic 
evaluations of gene mutational status and LOH in a number of published studies. 
Technically, these studies usually relied on direct DNA sequencing and microsatellite 
analysis with polymorphic markers. In the vast majority of these studies the tumour 
DNA used for the analyses derived from whole tumour homogenates, i.e. mixtures of 
tumour cells and stromal cells. Provided that a reasonable (usually > 30%) fraction of 
tumour is included in the sample this type of study material is quite sufficient for 
finding a gene mutation by sequencing. However, documenting LOH by microsatellite 
analysis with polymorphic markers with DNA from such homogenates is not possible: 
this technique does not allow for a distinction between LOH and AI; in fact, the so-
called LOHs reported for genes in most studies in reality are AI. This drawback of 
allelotyping analyses can only be overcome if tumour xeno-grafts, tumour cell lines or 
tumour cells isolated by laser-capture microdissection are used.  
TP53 is a well known TSG involved in DNA repair process and it fulfils the cardinal 
criteria of TSGs participating in the suppressor pathway by loss of function during 
tumour initiation or progression. In contrast, much less is known about PTEN as a 
TSG. It is reported to be deleted in various types of tumours and known to contribute 
to the inhibition of the cell cycle and cell survival. However, presently it is not clear if 
PTEN inactivation in colorectal cancer indeed proceeds by cellular mechanisms of 
the suppressor pathway. Using DNA from 18 colorectal cancer specimens (15 tumour 
xenografts, 2 tumour cell lines, and 1 laser capture micro-dissected primary tumour) 
this study addresses this issue.  
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The significant impact of TP53 aberrations in colorectal cancer is highlighted by the 
observation of TP53 mutations in 72% of the tumours in this series and the fact that 
mutations mapped to the highly conserved gene domains that are important for gene 
product function. The prevalence of TP53 mutations frequency in this study is in line 
with previous reports on TP53 mutation in sporadic colorectal cancer (Goh HS et al, 
1995; Russo A et al, 2005).  Furthermore, consistent with the notion that inactivation 
of p53 function by both mutation and LOH is essential in the progress to CRC we 
found that p53 gene mutation was combined with LOH in 56% of the tumours.  
Allelotyping by polymorphic marker analyses with the tumour material used in this 
study allowed to distinguish efficiently between true allelic loss and allelic imbalance: 
using this type of material, in the case of LOH (N=13 for TP53), complete loss of the 
PCR product corresponding to one allele was observed in the electropherograms, 
whereas only a shift of the tumour/normal ratios was seen in the case of AI (N= 3 for 
TP53). However, applying polymorphic microsatellite marker analyses to DNA from 
the whole tissue homogenates only AI was recorded for all the cases. 
Thiagalingam S et al, 2001 analysed early passage cell lines and xenografts in a 
series of 62 colorectal carcinomas. In accordance with our observations “true” TP53 
LOHs were detected in 73% of their tumours. Other published studies that addressed 
allelic loss by the usual technique of using DNA from whole tumour homogenates, 
had lower percentages of LOHs with a range from 50-68% (Kanazawa T et al, 2002; 
Sugai T et al, 2006). Conceivably, contaminating effects of non-neoplastic tissue 
masked the deletions and led to lower rates.  
Taken together, the molecular features observed for TP53 in this study were, as 
expected, those of a tumour suppressor gene, i.e. an inactivating mutation of one 
allele was seen to combine with genomic loss of the other allele. These findings 
attest to the proficiency of the methods used. They also highlight the fact that the 
common approach of allelotyping with whole tumour homogenates results in a 
significant fraction of spurious LOH calls.  
Traditionally, TP53 immunohistochemistry has been used as a surrogate method to 
test for TP53 mutations. The methods adopted in this study allowed, as a corollary, to 
assess if this is a valid assumption. Assuming unequivocal nuclear immunostaining of 
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>10% of tumour cells as a cut-off for classifying a case as positive by TP53 
immunohistochemistry sensitivity and specificity for detecting gene mutation by 
immunohistochemistry was calculated as 85% and 60%, respectively. This is in 
accord with previous published studies on this issue (Nasierowska-Guttmejer A et al, 
2000 and Slebos RJ et al, 1996). Many TP53 gene mutations are point mutations 
that do not truncate the protein but alter its conformation and inhibit its degradation 
(Iacopetta B, 2003).  This provides an elegant explanation for the fact that a large 
proportion of mutated tumours can be detected by immunohistochemical TP53 
overexpression. However, there remains a significant proportion of tumours escaping 
detection, and, overall, TP53 immunohistochemistry does not appear to be 
sufficiently sensitive and/or specific to be useful as a surrogate for gene sequencing.  
Applying these methods to the PTEN gene a different picture emerged. First, the 
PTEN gene was affected by mutation only in a single tumour, although, remarkably, 
in this tumour a total of three different mutations were seen. Second, two tumours 
were found to have LOH, but the tumour with mutations was not among these. Third, 
AI was observed in 6 cases, making this a fairly common event. The obvious 
conclusions from these findings is that in this series of colorectal carcinomas the 
“canonical” tumour suppressor gene features were not observed, raising some doubt 
about the universal conception of PTEN as a common TSG in this type of cancer. 
However, the following points merit comment as follows:  
1. Apparently, PTEN gene mutations are a rare event in microsatellite stable 
colorectal carcinomas, as investigated in this series. The low PTEN gene mutation 
frequency shown in this study is in accord with the results reported by Zhou XP et al, 
2002 and Shin KH et al, 2001 who studied a series of 39 and 32 microsatellites 
stable colorectal cancers, respectively: not a single case studied by these authors 
was reported positive for a PTEN gene mutation. In another two series of 20 and 327 
unselected microsatellite stable colorectal carcinomas, (Negoro K et al, 2000 and LI 
XH et al, 2009) PTEN gene mutations were found in 0 and 1 case, respectively.  
However, PTEN gene mutations were reported as fairly frequent among CRCs with 
high degree microsatellite instability (Day FL et al, 2013; Dicuonzo G et al, 2001; 
Guanti G et al, 2000), and this is well explained by these cancers’ incapacity of the 
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mismatch repair system to remove misincorporated nucleotides in the nucleotide 
repeats that are frequent in the downstream coding regions of the PTEN gene.  
Accordingly, PTEN gene mutations were observed in 3 out of 9 microsatellite instable 
colorectal cancers in a complementary study of the PTEN gene by our group (Hühns 
M et al, 2014).  
Taken together, PTEN gene mutation could be relevant for CRCs driven by 
microsatellite instability rather than those driven by chromosomal instability, arguing 
against the hypothesis that PTEN plays a tumour suppressor gene role in the 
classical sense.  
2. Gene promoter methylation is an alternative mechanism of gene inactivation and 
may substitute for mutation or allelic loss in the suppressor pathway. PTEN gene 
promoter methylation in colorectal carcinoma has been demonstrated by methylation-
specific PCR in previous studies (Goel A et al, 2004), giving rise to the hypothesis 
that a combination of promoter methylation with mutation or allelic loss could be the 
tumour suppressor gene mechanism. However, when PTEN gene promoter 
methylation was tested quantitatively by our group in an additional study of 42 cases 
by MethyLight technology, (Hühns M et al, 2014), epigenetic PTEN silencing was 
observed in a single case only, and this tumour did not have a PTEN gene mutation 
or PTEN allelic loss. 
3. In our series of colorectal carcinomas, LOH was seen in 11% of the tumours, but 
AI was observed in 33%, the latter figure corresponding quite well to the “LOHs” 
reported for the PTEN gene locus in previous publications (Frayling IM et al, 1997; 
Nassif NT et al, 2004; Garcia JM et al, 2003; Karoui M et al, 2004). These previous 
studies used DNA from whole tissue homogenates. As cautioned by Devilee et al 
2001, such type of study is not a study of LOH but of allelic imbalance, and, 
accordingly, what was reported as “LOH” in previous studies in reality was AI, with a 
doubtful functional role in tumorigenesis. 
When studying PTEN expression in our tumours by immunohistochemistry, a 
significant reduction, or even loss of PTEN expression was a frequent event, seen in 
13 of the 18 tumours amenable to this study (72%). Considering the well-established 
function of PTEN in cell cycle control and cell migration, this observation points to a 
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definite role of PTEN in colorectal carcinoma tumour biology, although apparently by 
mechanisms different from what is usually meant when referring to PTEN as a 
tumour suppressor gene: the most plausible mechanism to explain reduction or even 
loss of PTEN expression in colorectal carcinoma cells at this juncture is (dys) 
regulation by unknown factors from the microenviroment that act on the tumour cells. 
This hypothetical explanation also allow for plasticity, i.e. it can explain fluctuations in 
downregulation and re-expression, and thus accounts for the somewhat 
inhomogenous pattern of expression observed by immunohistchemistry in many of 
the cases.  
Reduced PTEN expression has been reported as a negative predictor for EGF-R 
blocking agents like cetuximab or panitumumab in the setting of metastasizing 
colorectal carcinoma (Razis E et al, 2008; Perrone F et al, 2009), underscoring its 
functional importance. Given the difficulties surgical pathologists usually encounter 
when trying to adapt quantitative/semi quantitative immunohistochemistry for routine 
use, testing the gene by molecular pathology instead would have been desirable: but 
alterations of PTEN expression are not appreciably mirrored in genomic aberrations, 
precluding this approach. 
In summary, the following main conclusions can be stated from these investigations: 
1. Counter to the common concept of a tumour suppressor gene, our study showed 
that for colorectal carcinoma the PTEN gene (in contrast to TP53) apparently is not 
typically targeted by two hits: the molecular features classically ascribed to a tumour 
suppressor gene, i.e. mutation of one allele and loss of the other is not usually 
observed.  
2. Nevertheless, as indicated by immunohistochemistry, PTEN gene expression 
apparently is dysregulated/downregulated, and likely has a role in colorectal cancer 
pathogenesis.  
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5. Appendix  
 
5.1. Sequences of primers for PCR of TP53 gene exons 5, 6, 7, and 8 with the length  
of amplicons 
 
Exon Forward primer (5‘→3‘) Reverse primer (5‘→3‘) 
Amplic. 
(bp) 
5 (GC40)TTCCTCTTCCTACAGTACTC CTGGGCAACCAGCCCTGTCGT 282 
6 (GC40)ACGACAGGGCTGGTTGCCCA AGTTGCAAACCAGACCTCAG 227 
7 (GC40)TCTCCTAGGTTGGCTCTGACTG GCAAGTGGCTCCTGACCTGGA 184 
8 CCTATCCTGAGTAGTGGTAATC (GC40)CCGCTTCTTGTCCTGCTTGCTT 215 
 
(GC40) = CGCCCGCCGCGCCCCGCGCCCGGCCCGCCGCCCCCGCCCG 
 
 
5.2. TGGE temperature gradient and running time for the different exons of TP53 
gene  
 
Exon Running Time at 20°C 
(min.) 
Temperature Gradient 
(°C) 
Running Time 
(min.) 
    
Exon 5 15 55/75 225 
Exon 6 100 35/68 170 
Exon 7 30 40/75 150 
Exon 8 180 40/78 180 
 
 4
3
 
 
    5.3. Sequences of primers for PCR and sequencing for P53 and PTEN genes with the length of amplicons 
 
Gene Exon Forward primer (5‘→3‘) Reverse primer (5‘→3‘) 
Amplicon 
(bp) 
TP53 2 and 3 TGGGGCAGGAGTGCTTGGGT TTGGGACGGCAAGGGGGACT 365 
 4 GCCATGGAGGAGCCGCAGTC AAGCCAGCCCCTCAGGGCAA 629 
 9 GAGCCTCACCACGAGCTGCC CCCCCTGATGGCAAATGCCCC 317 
 10 TTGCTGCAGATCCGTGGGCG AGGGCCAGGAAGGGGCTGAG 145 
 11 CGTTGTCCCAGCCTTAGGCCC TGGAGCCCCGGGACAAAGCA 337 
     
PTEN 1 CAGCCGTTCGGAGGATTA ATATGACCTAGCAACCTGACCA 484 
 2 GTACTTTAGTTCTGTGATGTATAAACCGT CTGAAGTCCATTAGGTACGGTAA 509 
 3 ATGTTTGTGAGGGTCGAATG GGACTTCTTGACTTAATCGGTTTAG 726 
 4 TTGAAAAAGGTGATCGTTGG ATTGTTATGACAGTAAGATACAGTCTATCG 657 
 5 TTCTGAGGTTATCTTTTTACCACA TCCAGGAAGAGGAAAGGAAAA 352 
 6 AATGTATATATGTTCTTAAATGGCTACGA TCATAAATATAATTTGGCTTCGACTAC 484 
 7 TGACAGTTTGACAGTTAAAGG GGATATTTCTCCCAATGAAAG 262 
 8 TGTCATTTCATTTCTTTTTCTTTTC AAGTCAACAACCCCCACAAA 305 
 9 GTTCATCTGCAAAATGGA TTTTCATGGTGTTTTATCCCTC 328 
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5.4. Sequences of primers, annealing temperatures, MgCl2 concentrations and the length of amplicons for LOH analysis 
 
 
N= A/C/G/T 
 
 
  
Gene Locus Forward primer (5‘→3‘) Reverse primer (5‘→3‘) 
Annealing 
temprature 
(˚C) 
MgCl2 Conc. 
(mM) 
Amplicon 
(bp) 
TP53 
D17S250 6-FAM-GGA AGA ATC AAA TAG ACA AT GCT GGC CAT ATA TAT ATT TAA ACC 55 2.75 151-169 
D17S1583 6-FAM- TGC CCA TGC TGA CAT A GAC CTG ACT AAA ANA CTC CA 57 1.5 103-139 
17p13.1 6-FAM- ACT GCC ACT CCT TGC CCC ATT C AGG GAT ACT ATT CAG CCC GAG GTG C 60 1.5 72-118 
PTEN 
D10S541 6-FAM- AAG CAA GTG AAG TCT TAG AAC CAC C CCA CAA GTA ACA GAA AGC CTG TCT C 60 1.5 247-273 
D10S579 6FAM- CCG ATC AAT GAG GAG TGC C ATA CAC CCA GCC AAT GCT GC 60 1.5 260-276 
D10S1765 6FAM- ACA CTT ACA TAG TGC TTT CTG CG CAG CCT CCC AAA GTT GC 60 1.5 166-184 
A
p
p
e
n
d
ix
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5.5. Materials and buffer solutions for  TGGE  
  
-  8% Polyacrylamid Gel 
21.6 g Urea 
12 ml Acrylamid 30% 
0.9 ml 50X MOPS 
2.25ml Glycerol 40% 
14.5ml aqua H2o 
0.34ml APS*  
 
75 μl TEMED ** 
Gel Bond PAG-Film (BIOzym) 
 
  50 x Mops 
9.3 g EDTA,*** 104.6 g MOPS **** 
500 ml Aqua dest ; the PH is to adjust with 5M NaOH to 8.  
 
- Silver staining 
Solutions: 
Puffer A: - 200 ml absolute Ethanol 
     - 10 ml glacial acid, fill up to 2 L with Aqua dest 
Puffer B: 1g AgNO3 silver nitrate in 1L Aqua dest 
Puffer C:  - 4.5g NaOH 
      - 0.05 g NaBH4  
      - 1.2 ml Formaldehyde 
                   fill up to 300 ml with Aqua dest 
Puffer D: 15 g Na2CO3 in 2 L Aqua dest 
Procedure 
Gel was shaken twice for 3 minutes in buffer A and for 10 minutes in buffer B. After 
rinsing twice briefly by Aqua dest, it was incubated for 20 minutes with shaking in 
buffer C and for 10 minutes in buffer D. 
*  Ammonium persulfate.                                                        **  Tetramethylethylendiamin. 
*** Ethylenediaminetetraacetic acid.                                      ****  3-(N-morpholino) propanesulfonic acid.                        
                                                                                                                                               References 
 46 
6. References  
 
Albuquerque C, Breukel C, van der Luijt, et al. The ‘just-right’ signalling model: 
APC somatic mutations are selected based on a specific level of activation of the 
ß-catenin signalling cascade. Hum Mol Genet 11: 1549 - 1560, 2002. 
 
Ali IU, Schriml LM & Dean M. Mutational Spectra of PTEN/MMAC1 Gene: A 
tumour suppressor with lipid phosphatase activity. J Nat Cancer Inst 91: 1922 - 
1932, 1999. 
 
Baast IO, Mulder JWR & Offerhaus GJ A. An evaluation of six antibodies for 
immunohistochemistry of mutant p53 gene product in archival colorectal 
neoplasms. J Path 172: 5 - 12, 1994. 
 
Baker SJ & Fearon ER, et al. Chromosome 17 deletions and p53 gene mutations 
in colorectal carcinomas. Science 244: 217 - 221, 1989. 
Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in 
combination with 17p allelic deletions as late events in colorectal tumorigenesis. 
Cancer Res 50: 7717 - 7722, 1990. 
 
Bartsch D, Barth P & Bastian Dl. Higher frequency of DPC4/Smad4 alterations in 
pancreatic cancer cell lines than in primary pancreatic adenocarcinomas. Cancer 
Letters 139: 43 - 49, 1999. 
 
Beach R, Chan AO, Wu TT, et al. BRAF mutations in aberrant crypt foci and 
hyperplastic polyposis. Am J Pathol. 166: 1069 - 1075, 2005. 
 
Berti L, Medintz IL, Tom J & Mathies RA. Energy-transfer cassette labelling for 
capillary array electrophoresis short tandem repeat DNA fragment sizing. Bio-
conjugate Chem. 12:  493 - 500, 2001. 
 
Bhattacharyya NP, Skandalis A, Ganesh A, Groden J & Meuth M. Mutator 
phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci 91: 6319 
- 6323, 1994. 
 
Bonneau D & Longy M. Mutations of the human PTEN gene. Hum Mut 16:109 - 
122, 2000. 
 
Broderick P, Carvajal-Carmona L, et al. A genome-wide association study shows 
that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 39: 
1315 - 1317, 2007. 
 
Cacev T, Jokic M, Spaventi R, et al. Loss of heterozygosity testing using real-time 
PCR analysis of single nucleotide polymorphisms. J Cancer Res Clin Oncol 132: 
200 - 204, 2006. 
 
Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in 
primary prostate cancer. Cancer Res  57: 4997 – 5000, 1997. 
 
                                                                                                                                               References 
 47 
Calvert PM & Frucht H. The genetics of colorectal cancer. Ann Intern Med 137: 
603 - 612, 2002. 
 
Cardoso J, Boer J, et al. Expression and genomic profiling of colorectal cancer. 
Biochim. Biophys Acta 1775: 103 - 137, 2007. 
 
Carracedo A, Alimonti A & Pandolfi PP PTEN Level in Tumour Suppression: How 
Much Is Too Little? Cancer Res 71: 629 - 633, 2011. 
 
Carvalho B, Postma C, et al. Multiple putative oncogenes at the chromosome 20q 
amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58: 79 - 
89, 2009. 
 
Chan TL, Yuen ST, Kong CK, et al. Heritable germline epimutation of MSH2 in 
family with hereditary nonpolyposis colorectal cancer. Nat Genet 38: 1178 - 1183, 
2006. 
 
Cheah PY. Recent advances in colorectal cancer genetics and diagnostics. Crit 
Rev Oncol Hematol 69: 45 - 55, 2009. 
 
Cho KR & Vogelstein B. Suppressor gene alterations in the colorectal adenoma-
carcinoma sequence. J  Cell Biochem 166:137 - 141, 1992. 
Cho KR, Oliner J.D, Simons JW, et al. The DCC gene: structural analysis and 
mutations in colorectal carcinomas. Genomics 19: 525 - 531, 1994. 
Chow LM & Baker SJ. PTEN function in normal and neoplastic growth. Cancer 
Letters 241: 184 – 196, 2006. 
 
Cui H, Cruz-Correa M, Giardello FM, et al. Loss of IGF2 imprinting: A potential 
marker of colorectal cancer risk. Science 299: 1753 - 1755, 2003. 
 
Dahia PL. PTEN, a unique tumour suppressor gene. Endocrine-Related Cancer 7: 
115 – 129, 2000. 
 
Danielsen SA, Lind GE, Bjørnslett M, et al.
 
Novel mutations of the suppressor 
gene PTEN in colorectal carcinomas stratified by microsatellite instability - and 
TP53 mutation status. Hum Mut 29: E252 – E262, 2008.  
Day FL, Jorissen RN, Lipton L, et al. PIK3CA and PTEN gene and exon mutation-
specific clinicopathologic and molecular associations in colorectal cancer. Clin 
Cancer Res. 19: 3285 – 3296, 2013. 
Devilee P, Cleton-Jansen AM, Cornelisse CJ. Ever since Knudson. Trends 
Genet 17: 569 - 573, 2001. 
 
Dicuonzo G, Angeletti S, Garcia-Foncillas J, et al. Colorectal carcinomas and 
PTEN/MMAC1 gene mutations. Clin Cancer Res 7:4049 - 4053, 2001. 
 
Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of 
PCR primers and protocols for detection of clonal immunoglobulin and T-cell 
                                                                                                                                               References 
 48 
receptors gene recombinations in suspect lymphoproliferations. Report of the 
BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17: 2301 - 2317, 2003. 
Duff EK & Clarke AR. Smad4 (DPC4) a potent tumour suppressor? Br J Cancer 
78: 1615 - 1619, 1998. 
Easton DF & Eeles RA. Genome-wide association studies in cancer. Hum Mol 
Genet 17: 109 - 115, 2008. 
 
Egger G, Liang G, Aparicio A et al. Epigenetics in human disease and prospects 
for epigenetic therapy. Nature 429: 457 - 463, 2004. 
 
Ellegren H. Microsatellite: Simple Sequence with complete evolution. Nature 
Reviews 5:  435 - 445, 2004.  
 
Ellsworth RE, Ellsworth DL, Lubert SM, et al. High-throughput loss of 
heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer 
Epid Biomarkers & Prevention 1: 915 – 919, 2003. 
 
Erhan Y, Korkut MA & Kara E. Value of p53 protein expression and its 
relationship  with short term  prognosis in colorectal cancer. Annuals of Saudi 
Medicine, 22: 377 - 379, 2002. 
 
Eshleman JR, Casey G, Kochera ME, et al. Chromosome number and structure 
both are markedly stable in RER colorectal cancers and are not destabilized by 
mutation of p53. Oncogene 17: 719 – 725, 1998. 
 
Esteller M.  CpG island hypermethylation and tumour suppressor genes: a 
booming present, a brighter future. Oncogene 21: 5427 –  5440, 2002. 
 
Fata JE, Debnath S, et al. Nongenomic mechanisms of PTEN regulation. Int J 
Cell Biol: 2012. 
 
Fearon ER & Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61: 
759 - 767, 1990.  
 
Feinberg AP & Tycko B. The history of cancer epigenetics. Nat Rev Cancer 4: 
143 - 153, 2004. 
 
Feinberg AP, Ohlsson R & Henikoff S. The epigenetic progenitor origin of human 
cancer. Nat Rev Genet 7: 21 - 33, 2006. 
 
Firestein R, Bass AJ, et al. CDK8 is a colorectal cancer oncogene that regulates 
beta catenin activity. Nature 455: 547 - 551, 2008. 
 
Forrester K, Almoguera C, Han K, Grizzle WE & Perucho M. Detection of high 
incidence of K-ras oncogenes during human colon tumorgenesis. Nature 327: 298 
- 303, 1987. 
 
                                                                                                                                               References 
 49 
Frayling IM, Bodmer WF & Tomlinson IPM. Allele loss in colorectal cancer at the 
cowden disease/ Juvenile Polyposis locus on 10q.  Cancer Genet Cytogenet 97: 
64 - 69, 1997.  
 
Garcia JM, Rodriguez R, Silva J, et al. Intratumoural heterogeneity in 
microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal 
cancer. Ann Surg Oncol 10: 876 - 881, 2003. 
 
Geiersbach KB & Samowitz WS. Microsatellite instability and colorectal cancer. 
Arch Pathol Lab Med135:1269 – 1277, 2011. 
 
Geigl JB, Obenauf  AC, Schwarzbraun T & Speicher MR. Defining chromosomal 
instability. Trends in Genetics 24: 64 - 69, 2008. 
 
Georgescu MM, Kirsch KH, Akagi T, Shishido T & Hanafusa H. The tumour-
suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl 
Acad Sci USA 96: pp. 10182 – 10187, 1999. 
 
Goel A, Arnold CN, Niedzwiecki D, et al. Characterization of sporadic colon 
cancer by pattern of genomic instability. Cancer Res. 63:1608 - 1614, 2003. 
 
Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by 
promoter hypermethylation in microsatellite instability-High sporadic colorectal 
cancers. Cancer Res 64: 3014 - 3021, 2004. 
 
Goh HS, Yao J & Smith DR. P53 point mutation and survival in colorectal cancer 
patients. Cancer Res 55: 5217 - 5221, 1995. 
 
Goldgar DE, Easton DF, et al. Systematic population-based assessment of 
cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86: 
1600 - 1608, 1994. 
 
Grady WM & Markowitz SD. Hereditary colon cancer genes. Methods Mol Biol 
222: 59 - 83, 2003. 
 
Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming 
growth factor beta receptor type II in microsatellite stable colon cancers. Cancer 
Res 59:  320 - 324, 1999. 
 
Grady WM, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth 
factor-beta receptors is coincident with the transformation of human colon 
adenoma to malignant carcinomas. Cancer Res 58: 3101 - 3104, 1998. 
 
Grady WM. Genomic instability and colon cancer. Cancer and Metastasis 
Reviews 23: 11 - 27, 2004. 
 
Gruis NA, Abeln ECA, Bardoell AFJ, et al. PCR-based microsatellite 
polymorphisms in the detection of loss of heterozygosity in fresh and archival 
tumour tissue. Br J Cancer 68: 308 - 313, 1993. 
 
                                                                                                                                               References 
 50 
Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P, Gentile M. 
Involvement of PTEN mutations in the genetic pathways of colorectal 
carinogenesis. Hum Mol Genet 9: 283 - 287, 2000. 
 
Hahn SA, Seymour AB, Hoque AT, et al. Allelotype of pancreatic adenocarcinoma 
using xenograft enrichment. Cancer Res. 55: 4670 - 4675, 1995. 
 
Harkes IC, Elstrodt F, Dinjens WNM, et al: Allelotype of 28 human breast cancer 
cell lines and xenografts. Br J Cancer 89: 2289  - 2292, 2003. 
 
Harris CC. P53: at the crossroads of molecular carcinogenesis and risk 
assessment. Science 262: 1980 - 1881, 1993. 
 
Heinmöller E, Dietmaier W, Zirngibl H, et al. Molecular analysis of microdissected 
tumours and preneoplastic intraductal lesions in pancreatic carcinoma. Am J 
Pathol 157: 83 - 92, 2000. 
 
Heldin CH, Miyazono K & ten Dijke P. TGF-ß signalling from cell membrane to 
nucleus through SMAD proteins. Nature 390: 465 - 471, 1997. 
 
Hitchins M, Williams R, Cheong K, et al. MLH1 germline epimuations as a factor 
in hereditary nonpolyposis colorectal cancer. Gastroenterology 129: 1392 - 1399, 
2005. 
 
Hoang JM, Cottu PH, Thuille B, et al. BAT-26, an indicator of the replication error 
phenotype in colorectal cancer and cell lines. Cancer Res 57: 300 - 303, 1997. 
 
Hollander MC, Blumenthal GM & Dennis PA. PTEN loss in the continuum of 
common cancers, rare syndromes and mouse models.  Nature 11: 289 - 301, 
2011. 
 
Huang CS, O’Brien MJ, Yang S, et al. Hyperplastic polyps, serrated adenomas, 
and the serrated polyp neoplasia pathway. Am J Gastroenterol 99: 2242 - 2255, 
2004. 
 
Hühns M, Salem T, Schneider B, Krohn M, Linnebacher M and Prall F. PTEN 
mutation, loss of heterozygosity, promoter methylation and expression in 
colorectal carcinoma: two hits on the gene? Oncol Rep: in press, 2014. 
 
Hsu CP, Kao TY, Chang WL, et al. Clinical significance of tumor suppressor 
PTEN in colorectal carcinoma. EJSO 37: 140 - 147, 2011. 
 
Iacopetta B. TP53 mutation in colorectal cancer. Hum Mut 21: 271 - 276, 2003. 
 
Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in 
simple repeated sequences reveal a new mechanism for colonic carcinogenesis. 
Nature 363: 558 – 561, 1993. 
 
Issa JP: Colon Cancer. It's CIN or CIMP. Clin Cancer Res 14: 5939 - 40, 2008. 
 
                                                                                                                                               References 
 51 
Jacob S & Praz F. DNA mismatch repair defects: role in colorectal 
carcinogenesis. Biochimie 84: 27 - 47, 2002. 
 
Jass JR, Iino H, Ruszkiewicz A, et al. Neoplastic progression occurs through 
mutator pathways in hyperplastic polyposis of the colorectum. Gut 47: 43 - 49, 
2000. 
Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in 
colorectal cancer. N Engl J Med 331: 213 - 221, 1994. 
Kanazawa T, Watanabe T, Kazama S, et al. Poorly differentiated adenocarcinoma 
and mucinous carcinoma of the colon and rectum show higher rates of loss of 
heterozygosity and loss of E-cadherin expression due to methylation of promoter 
region. Int J Cancer 102: 225 - 229, 2002. 
 
Karoui M, Tresallet C, Julie C. Loss of heterozygosity on 10q and mutational 
status of PTEN and BMPR1A in colorectal primary tumours and metastases. Br J  
Cancer 90: 1230 - 1234, 2004. 
Keino-Masu K, Masu M, Hinck L, et al. Deleted in colorectal cancer (DCC) 
encodes a netrin receptor. Cell 87: 175 - 185, 1996. 
Kim EC & Lance P. Colorectal polyps and their relationship to cancer. 
Gastroenterol Clin North Am 26: 1 - 17, 1997. 
Kinzler K.W. & Vogelstein B. Lessons from Hereditary colorectal cancer. Cell 87: 
159 - 170, 1996. 
 
Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci 90: 10914 - 
10921, 1993. 
 
Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a b-
catenin–Tcf complex in APC-/- colon carcinoma. Science 275: 1784 - 1787, 1997. 
 
Kubbutat MH, Jones SN & Vousden KH. Regulation of p53 stability by Mdm2. 
Nature 387: 299 - 303, 1997. 
 
Kurose K, Zhou XP, Araki T, et al. Frequent loss of PTEN expression is linked to 
elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 
expression, in primary epithelial ovarian carcinomas. Am J Pathol 158: 2097- 
2106, 2001. 
 
Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in 
familial adenomatous polyposis is determined by the site of the germline mutation: 
a new facet to Knudson’s ‘two-hit’ hypothesis. Nat Med 5: 1071 - 1075, 1999. 
 
Lane DP. p53, guardian of the genome. Nature 358: 15 - 16, 1992. 
 
Lasko D, Cavenee W, Nordenskjold M. Loss of constitutional heterozygosity in 
human cancer. Annual Rev Genet 25: 281 - 314, 1991. 
 
                                                                                                                                               References 
 52 
Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumour 
suppressor: implications for its phosphoinositide phosphatase activity and 
membrane association. Cell 99: 323 - 334, 1999. 
 
Lengauer C, Kinzler KW & Vogelstein B. Genetic instabilities in human cancers. 
Nature 396: 643 - 649, 1998. 
 
Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma-carcinoma sequence. 
Br J Surg 89: 845 - 860, 2002. 
 
Levine AJ, Hu W, et al. The P53 pathway: what questions remain to be explored? 
Cell Death Differ 13: 1027 - 1036, 2006. 
 
Li AG, Piluso LG, Cai X, Weiet G, et al. Mechanistic insights into maintenance of 
high p53 acetylation by PTEN. Molecular Cell 23: 575 - 587, 2006. 
 
Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene 
mutated in human brain, breast, and prostate cancer. Science 275: 1943 - 1947, 
1997. 
 
Li XH, Zheng HC, Takahashi H, et al. PTEN expression and mutation in colorectal 
carcinomas. Onc Reports 22: 757 - 764, 2009. 
 
Lin MS, Huang JX, Chen WC, et al. Expression of PPARγ and PTEN in human 
colorectal cancer: An immunohistochemical study using tissue microarray 
methodology Oncology Leteres 2: 1219 - 1224, 2011. 
 
Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, Prall F. 
Cryopreservation of human colorectal carcinomas prior to xenografting. BMC 
Cancer 10: 362, 2010.  
 
Lo KW, Teo PML, Hui ABY, et al. High resolution allelotype of microdissected 
primary nasopharyngeal carcinoma. Cancer Res 60: 3348 - 3353, 2000. 
 
Lothe RA, Nakamura Y, Woodward S, et al. VNTR (variable number of tandem 
repeats) markers show loss of chromosome 17p sequences in human colorectal 
carcinomas. Cytogenet Cell Genet 48:167 - 169, 1988. 
 
Lynch HT & de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 348: 
919 - 932, 2003. 
 
Lynch HT & Lynch J. Lynch syndrome: genetics, natural history, genetic 
counselling, and prevention. J Clin Oncol 18:19 - 31, 2000. 
 
Macleod K. Tumour suppressor genes. Current opinion in genetics & 
development 10: 81 - 93, 2000. 
 
Maehama T & Dixon JE. PTEN: a tumour suppressor that functions as a 
phospholipid phosphatase. Trends Cell Biol 9:125 - 128, 1999. 
                                                                                                                                               References 
 53 
Malkin D, Jolly KW & Barbier N. Germline mutations of the p53 tumour-
suppressor gene in children and young adults with second malignant neoplasms. 
N Engl J Med 326: 1309 - 1315, 1992. 
McLure KG. & Lee PW. How p53 binds DNA as a tetramer. EMBO J 17: 3342 - 
3350, 1998. 
 
McQueen HA, Wyllie AH, Piris J, et al. Stability of critical genetic lesions in human 
colorectal carcinoma xenografts. Br J Cancer 63: 94  - 96, 1991. 
 
Medintz IL, Lee CC, Wong WW, et al: Loss of heterozygosity assay for molecular 
detection of cancer using energy-transfer primers and capillary array 
electrophoresis. Gen Res 10: 1211 - 1218, 2000. 
 
Michor F, Iwasa Y, Vogelstein B, et al. Can chromosomal instability initiate 
tumorigenesis? Seminars in Cancer Biology 15:  43 - 49, 2005. 
 
Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in 
colorectal tumours: mutation cluster region in the APC gene. Hum Mol Genet 1: 
229 - 233, 1992. 
 
Monte NM, Webster KA, Neuberg D, et al. Joint loss of PAX2 and PTEN 
expression in endometrial precancers and cancer. Cancer Res 70:  6225 - 6232, 
2010. 
 
Morin PJ, Sparks AB, Korinek V, et al: Activation of ß catenin-Tcf signalling in 
colon cancer by mutation in ß-catenin or APC. Science 275:1787 - 1790, 1997. 
 
Mutter GL, Lin MC & Fitzgerald JT. Altered PTEN expression as a diagnostic 
marker for the earliest endometrial precancers. J  Natl Cancer Inst 92: 924 - 931, 
2000. 
 
Nasierowska-Guttmejer A, Trzeciak L, Nowacki MP, Ostrowski J. P53 protein 
accumulation and p53 gene mutation in colorectal cancer. Pathol Oncol Res 6: 
275 - 279, 2000. 
 
Nassif NT, Lobo GP, Wu X, et al. PTEN mutations are common in sporadic 
microsatellite stable colorectal cancer. Oncogene 23: 617 - 628, 2004. 
 
Negoro K, Takahashi S, Kinouchi Y, et al. Analysis of the PTEN gene mutation in 
polyposis syndromes and sporadic gastrointestinal tumours in Japanese patients. 
Dis Colon  Rectum 43: 29 - 33, 2000.  
 
Nowak MA, Komarova NL, Sengupta A, et al. The role of chromosomal instability 
in tumour initiation.  PNAS 99: 16226 - 16231, 2002.    
 
Ogino S, Brahmandam M, Kawasaki T, et al. Epigenetic profiling of synchronous 
colorectal neoplasias by quantitative DNA methylation analysis. Modern Path. 19: 
1083 -1090, 2006.  
 
                                                                                                                                               References 
 54 
Parsons R, Li GM, Longley MJ, Fang WH, et al: Hypermutability and mismatch 
repair deficiency in RER + tumour cells. Cell 75:1227 - 1236, 1993. 
 
Parsons R, Myerof LL, Liu B, et al. Microsatellite instability and mutations of 
transforming growth factor beta type II receptor gene in colorectal cancer. Cancer 
Res 55: 5548 - 5550, 1995. 
 
Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon 
cancer. Hum Mol Genet 10: 735 - 740, 2001. 
 
Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analyses 
reveal differential subcellular compartmentalization of PTEN in endocrine 
pancreatic tumours compared to normal islet cells. Am J Pathol 157: 1097 - 1103, 
2000. 
 
Perren A, Weng LP, Boag AH, et al: Immunohistochemical evidence of loss of 
PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 
155:1253 - 1260, 1999. 
Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes 
to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann 
Oncol  20: 84 - 90, 2009. 
Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during 
colorectal tumorgenesis. Nature 359: 235 - 237, 1992. 
 
Razis E, Briasoulis E, Vrettou E, et al. Potential value of PTEN in predicting 
cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 8: 
234 -  244, 2008. 
 
Reyes G, Villanueva A, Garcia C, et al. Orthotopic xenografts of human 
pancreatic carcinomas acquire genetic aberrations during dissemination in nude 
mice. Cancer Res 56: 5713 - 5719, 1996. 
 
Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international 
collaborative study on the prognostic and predictive significance of p53 mutation: 
Influence of tumour site, type of mutation, and adjuvant treatment. J Clin Oncolo 
23: 2005. 
Sugai T, Habano W, Jiao YF, et al. Analysis of molecular alterations in left- and 
right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: 
proposal for new molecular profile of colorectal carcinomas. J Mol Diagn 8:193 - 
201, 2006. 
Saha S, Bardelli A, Buckhaults P, et al: A phosphatase associated with 
metastasis of colorectal cancer. Science 294: 1343 - 1346, 2001. 
Salmena L, Carracedo A & Pandolfi PP. Tenets of PTEN tumour suppression. 
Cell 133: 403 - 404, 2008. 
 
                                                                                                                                               References 
 55 
Sawai H, Yasuda A, Ochi N, et al. Loss of PTEN expression is associated with 
colorectal cancer liver metastasis and poor patient survival. BMC 
Gastroenterology 8:56, 2008. 
 
Scholz RB, Mllde-Langosch K, Jung R, et al. Rapid screening for Tp53 mutations 
by temperature gradient gel electrophoresis: a comparison with SSCP analysis. 
Hum Mol Genet 2:  2155 - 2158, 1993. 
 
Shin KH, Park YJ & Park JG. PTEN gene mutations in colorectal cancer 
displaying MSI. Cancer letters 174:189 - 194, 2001. 
 
Skotheima RI, Diepa CB, Kraggeruda SM, et al. Evaluation of loss of 
heterozygosity/allelic imbalance scoring in tumour DNA. Cancer Genet. & 
Cytogenet. 127: 64 - 70, 2001. 
 
Slebos RJ, Baas IO & Clement M. Clinical and pathological associations with p53 
tumour-suppressor gene mutations and expression of p21WAF1/CiP1 in 
colorectal carcinoma. Br J Cancer 74: 165 - 171, 1996. 
 
Smits R, Kielman MF, Breukel C, et al. Apc1638T: a mouse model delineating 
critical domains of the adenomatous polyposis coli protein involved in 
tumorigenesis and development. Genes Dev 13: 1309 - 1321, 1999. 
 
Solomon E, Voss R, Hall V, et al. Chromosome 5 allele loss in human colorectal 
carcinomas. Nature 328: 616 - 619, 1987. 
 
Song MS, Carracedo A, Salmena L, et al. Nuclear PTEN regulates the APC-
CDH1 tumour suppressive complex in a phosphatase-independent manner. Cell 
144: 187 - 199, 2011. 
 
Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour 
suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple 
advanced cancers. Nat Genet 15: 356 - 362, 1997. 
 
Suter CM, Martin DI & Ward RL. Germline epimutation of MLH1 in individuals with 
multiple cancers. Nat Genet 36: 497 - 501, 2004. 
 
Taniyama K, Goodison S & Ito R, et al. PTEN expression is maintained in 
sporadic colorectal tumours. J Pathol194: 341 - 348, 2001. 
 
Thiagalingam S, Laken S, Willson JK, et al. Mechanisms underlying losses of 
heterozygosity in human colorectal cancers. Proc Natl Acad Sci USA. 98: 2698 - 
2702, 2001. 
 
Thibodeau SN, Bren G & Schaid D. Microsatellite instability in cancer of the 
proximal colon. Science 260: 816 - 819, 1993. 
 
Tomlinson IP, Lambros MB & Roylance RR. Loss of heterozygosity analysis: 
Practically and conceptually flawed?. Genes Chromosomes & Cancer 34: 349 - 
353, 2002. 
 
                                                                                                                                               References 
 56 
Uronis JM, Osada T, McCall S, et al. Histological and molecular evaluation of 
patient-derived colorectal cancer explants. PLos One 7:  2012. 
 
Venkatachalam S, Shi YP, et al. Retention of wild-type p53 in tumours from p53 
heterozygous mice: reduction of p53 dosage can promote cancer formation. 
EMBO J 17: 4657 - 4667, 1998. 
 
Vilar E & Gruber SB. Microsatellite instability in colorectal cancer-the stable 
evidence. Nat Rev Clin Oncol advance online publication, 2010. 
 
Vogelstein B & Kinzler KW. Cancer genes and the pathways they control. Nat 
Med 10: 789 - 799, 2004. 
Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal 
tumour development. N Engl J Med 319: 525 - 532, 1988. 
Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. 
Science 244: 207 - 211, 1989. 
Vousden KH & Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2: 
594 - 604, 2002. 
 
Vousden KH & Prives C. P53 and prognosis: new insights and further complexity. 
Cell 120: 7 -10, 2005. 
 
Waite KA & Eng C. Protein PTEN: form and function. Am J Hum Genet. 70: 829 - 
844, 2002. 
 
Waniczek D, Snietura M, Liszka JM, et al. PTEN expression profiles in colorectal 
adenocarcinoma and its precancerous lesions. Pol J Pathol 1: 15 - 20, 2013. 
 
Weber JC, Schneider A, Rohr S, et al. Analysis of allelic imbalance in patients 
with colorectal cancer according to stage and presence of synchronous liver 
metastases. An Surg 234: 795 - 803, 2001. 
 
Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumour suppressor 
PTEN/MMAC1 in advanced human prostate cancer through loss of expression. 
Proc Natl Acad Sci U S A 95: 5246 - 5250, 1998. 
 
Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast 
and colorectal cancers. Science 318: 1108 - 1113, 2007. 
 
Zhou XP, Gimm O, Hampel H, et al. Epigenetic PTEN silencing in malignant 
melanomas without PTEN mutation. Am J Pathol157: 1123 - 1128, 2000. 
 
Zhou XP, Loukola A, Salovaara R, et al. PTEN mutational spectra, expression 
levels, and subcellular localization in microsatellite stable and unstable colorectal 
cancers. Am J Pathol 161: 439 - 447, 2002.  
 
57 
7. Declaration of original work 
 
 
 
I hereby declare that the work presented here is, to the best of my knowledge and 
belief original and the results of my own investigations, except as acknowledged, and 
has not been submitted, either in part or whole, for a degree at this or any other 
University. Formulations and ideas taken from other sources are cited as such. This 
work has not been published.  
 
 
Tareq Salem          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
8. Thesis for dissertation  
1. The phosphatase and tensin homologue (PTEN) gene encodes a major 
tumour suppressor protein involved in the control of cell growth and 
proliferation by counteracting cellular growth signals. A combination of PTEN 
gene mutation with allelic loss (loss of heterozygosity, LOH) has previously 
been shown in various types of cancer, suggesting a role for PTEN as a 
tumour suppressor gene as specified by knudsons’s classical “two-hit” 
concept.  
 
2. Although the suggestion has been made in the literature, detailed studies of 
PTEN in colorectal carcinoma have not been made to test if PTEN actually 
meets the two-hit criteria for a tumour suppressor gene in the classical sense. 
 
3. This study was conducted to find out if the patterns of PTEN gene molecular 
aberration in colorectal carcinoma are consistent with the classic molecular 
features ascribed to a tumour suppressor gene. To this end, PTEN gene 
mutations and LOH were assayed in a series of 18 colorectal carcinomas. 
Since loss of gene function by a tumour suppressor gene mechanism is a 
cardinal feature of tumours with chromosomal instability, this series was 
composed of non-familial microsatellite-stable colorectal carcinomas (so-called 
sporadic standard type).  
 
4. Tumour DNA from colorectal carcinoma xenografts/primary cell lines (N = 17) 
or neoplastic glands isolated by laser capture microdissection (N = 1) was 
used for gene sequencing and allelotyping analyses; gene expression in 
primary tumour tissues was additionally tested by immunohistochemstry. 
TP53, a paradigm tumour suppressor gene, was studied in parallel for 
comparison and validation of the methods.  
 
5. TP53 gene mutations were found in 13 (72%) of the tumours, 10 of which 
(56% of the total) also had a demonstrable loss of one TP53 allele. Overall, 11 
tumours were classified as positive by TP53 immunohistochemistry. 
Sensitivities and specificities for detecting gene mutation by 
immunohistochemistry were 85% and 60%, respectively.   
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6. PTEN gene mutation was a rare event in this series. Sequencing of exons 1 - 
9 revealed a total of 3 different somatic mutations, but restricted to a single 
tumour. Polymorphic microsatellite marker analyses showed LOH in 2 tumours 
and allelic imbalance (AI) in 6 tumours. LOH or AI did not target the 1 tumour 
with the PTEN gene mutations. By immunohistochemistry, reduced or even 
loss of PTEN expression was a frequent observation, found in 12 and 1 of the 
tumours, respectively.  
 
7. This study confirms the universally accepted role of TP53 as a tumour 
suppressor gene in colorectal carcinoma. This result validates the methods in 
their extension to the study of the PTEN gene.   
 
8. Contrary to TP53, PTEN gene mutations are an infrequent event in colorectal 
carcinomas with chromosomal instability, and, additionally, LOH in its strict 
sense also is not a common feature, although AI is not unusual. Contrary to 
the allelotyping studies in this work that relied on pure tumour DNA, previous 
studies addressing PTEN LOH in colorectal carcinoma used DNA from whole 
tumour homogenates which, technically, does not allow proper distinction 
between LOH and AI. Thus, the high rates of “LOH” reported in the literature 
are spurious and in reality were AI. 
 
9. From these findings we conclude that PTEN gene is not typically targeted by 
two hits: the molecular features classically ascribed to a tumour suppressor 
gene, i.e. mutation of one allele and loss of the other is not usually observed. 
The widely held belief of PTEN as a classical tumour suppressor gene is not 
supported by the findings from this study.  
